annual report p e n p e p l e p r n e r positive latestage clinical study keeping pace emerging new collaborations results investigational market growth aiming strategic partnership established medicine ocrelizumab multiple increase representation foundation medicine help sclerosis give hope people living people established drive innovation provide disease need developing region experience new possibilities rd treatment options key leadership positions improved patient carecontents overview highlights chairmans shareholder letter ceos shareholder letter business review annual performance market environment diagnostics sales performance transforming laboratory practice pharmaceuticals sales performance key regulatory milestones innovation rd overview personalised cancer immunotherapy pharmaceuticals pipeline newsflow access healthcare countryspecific access planning innovative pricing access models cover responsible business applying innovative cell culture methods christoph patsch phd laboratory head culture compliance roche innovation center basel recreates human diseases dish patientspecific cells managing opportunity risk provide valuable model study underlying disease biology ultimately identify novel putting patient safety first drug targets therapeutic approaches people expanding diversity inclusion committed leadership environment community safety security health environment philanthropic engagement corporate governance report board directors corporate executive committee remuneration report principles remuneration componentsroche roche w ho innovation dna worlds largest biotech company develop always worked across breakthrough medicines improving standard biotech oncology vitro ofcare across oncology immunology infectious diagnostics hospital market disciplines geographies diseases ophthalmology neuroscience also world leader vitro diagnostics drive scientific discovery business track record allows us build lasting redefine possible meaningful partnerships across world roche medicines research academia public healthcare institutions essential medicines list improve patients lives founding families continue hold majority working understanding diseases stake company stability allows differ molecular level develop tradition sustainable thinking learn new tests medicines prevent diagnose setbacks focus lasting value patients employees countries treat diseases matter bring society remain dedicated highest patients need combined strengths standards quality safety integrity legacy diagnostics pharmaceuticals personalised based respect individual well chf bn healthcare strategy aims fit right treatment communities world live right patient group sales roche roche focus patients excellence science personalised healthcare disease awareness treatment product portfolio strategy rd pipeline strategy education patent policies personalised healthcare patient organisation support data transparency clinical trials details see pharmaceuticals diagnostics drug efficacy safety counterfeiting details see innovation responsible innovation chapters biosimilar safety business chapters details see pharmaceuticals diagnostics w hat access healthcare responsible business chapters access healthcare great workplace sustainable value researchbased conducted materiality analysis global healthcare company corporate level amongst key stakeholders map important topics related combined strengths priorities pharmaceuticals result identified material topics diagnostics stood highly relevant us key stakeholders significant economic develop manufacture deliver innovative environmental social impact material medicines diagnostic instruments tests topics reflected business priorities help millions patients globally clear concrete actions related sustainable healthcare employee engagement environmental responsibility set priorities aim achieve sustainable operational activities growth strategy emerging talent retention compliance growth deliver value stakeholders developed markets compensationbenefits occupational accidents pricing leadership commitments community engagement details see access healthcare chapter organisational effectiveness supply chain management executive compensation details see responsible business details see people chapter environment community chapters remuneration report information materiality process outcomes see wwwrochecommateriality roche highlights highlights roche hig hlig ht partnership foundation medicine fda breakthrough therapy designation fda breakthrough therapy designation carbon disclosure project recognition molecular information venetoclax two forms leukemia emicizumab ace hemophilia climate change mitigation us approval lucentis fda breakthrough therapy designation positive phase iii results ocrelizumab fda approval cobas hbv cobas hcv us approval alecensa diabetic retinopathy actemra systemic sclerosis two forms multiple sclerosis cobas hiv viral load tests type lung cancer december january eu approval avastin positive phase ii results atezolizumab eu approval perjeta regimen launch first roche first national hpv primary us eu approval cotellic plus advanced cervical cancer advanced bladder cancer early breast cancer pcr liquid biopsy test screening tender europe zelboraf advanced melanoma fda breakthrough therapy designation fda clearance cobas flu ab test dow jones sustainability indices leader positive phase iii results gazyvagazyvaro atezolizumab type lung cancer use cobas liatsystem healthcare th year running type nonhodgkin lymphoma leukemia roche chairmans shareholder letter chairmans shareholder letter roche remaining sustainably successful successful research development new tests medicines improving access medical solutions key sustainable development business dear shareholders continue contribute achieving goal main contribution developing tests sales grew strongly across two divisions medicines meet urgent pharmaceuticals diagnostics enabled us medical needs post net income chf billion despite substantial appreciation swiss franc owe area diagnostics particular primarily dedication passion likely play significant role future employees thank every one enables health managed effectively prevention targeted therapy unfortunately also stand memories monitoring chronic disordersand still year wars terror epidemics many lot untapped potential events affected personally employees former colleagues friends harmed part strategic focus longterm success know crisis regions well also conducting research fields successful year father five children also ask probability success particularly high continue justice future generations medical need greater want drive past years global economy doubled size progress medical options available patients global ecological footprint latter neurological diseases endeavour many times greater environment recently produced strong results trials roche bear longer term investigating treatment multiple sclerosis background encouraged furthermore encouraged opportunities new sustainable development goals adopted opened information technology aim member states united nations september turn wealth medical data valuable one goals good health well knowledge aid research selection christoph franz global healthcare company roche therapies individual patient chairman board roche chairmans shareholder letter chairmans shareholder letter roche light strong performance therefore delighted finalised partner resulting improved insights specific regional light strong performance positive ship agreements foundation medicine national challenges local level tailored outlook board directors proposing proposing another dividend flatiron health field oncology plans address dividend increase chf per share non relationships lead improvements voting equity security subject approval increase outcomes cancer patients aware worlds poorest countries th dividend increase many years patents present hurdle provision important us therapies reach basic medical care register addition reelection existing members patients need countries enforce patent rights countries agm see changes board since company founded nearly years ago latest medicines diagnostics freely affluent countries however patents create directors already aware dame deanne roche always questioned status quo set available others even basic things incentives needed highrisk investments julius member board directors since new standards lacking take example hivaids patent expired society benefits professor dr beatrice weder di mauro board enough distribute medicines cost price important medicines become permanently available member since decided stand great pleasure part insufficient healthcare workers facilities reduced cost proud medicines reelection made extraordinarily innovative company assure diagnostic tools administer therapies correctly developed feature world health valuable contributions many years continue everything power ensure working overcome hurdles organisation essential medicines list among companys successful development behalf company continues deliver scientific partnership public private stakeholders lifesaving antibiotics malaria cancer medicines roche board directors would like extend excellence benefit patients future would like mention hiv global sincerest thanks access programme launched innovative healthcare company regard would like thank shareholders partners unaids joint united nations sustainability responsibility growth delighted able propose julie brown confidence company programme hivaids clinton health driver recent recognition demonstrates dr claudia sssmuth dyckerhoff new access initiative aim programme efforts successful roche healthcare members board directors provide certain lowincome countries long company awarded maximum score wealth international management experience term supplies hiv viral load tests nonprofit organisation cdp formerly chief financial officer british medical carbon disclosure project leading ranking technology company smith nephew julie brown question access new products inevitably companies responses climate change extensive knowledge sales finance ethical component take issue seriously seventh time row roche identified healthcare industry claudia sssmuth dyckerhoff want help patients gain access products sustainable healthcare company currently senior partner consulting firm including countries low purchasing power dow jones sustainability indices mckinsey company leader christoph franz roche one first companies established healthcare systems services practice asia chairman board differentiated pricing policy developing regions awards mean satisfied advanced access planning strategy status quo must renew efforts every day stay ahead game live strong commitment sustainable named company applies everything sustainable healthcare company ladies gentlemen look forward welcoming th annual general meeting agm world every year since roche holding ltd march would like take opportunity mention two important items agenda roche board directors board directors roche board directors left right bernard poussot c e paul bulcke b e peter r voser c e prof dr beatrice weder di mauro b e dr severin schwan f dame deanne julius b e dr christoph franz chairman c e andr hoffmann vicechairman representative shareholder group pooled voting rights c e dr andreas oeri representative shareholder group pooled voting rights e prof sir john irving bell b e prof dr richard p lifton e prof dr pius baschera e corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson roche board directors december roche ceos shareholder letter ceos shareholder letter roche great year pipeline successful year made great strides innovating medicines patients difficulttotreat diseases including multiple sclerosis different types cancer hemophilia dear shareholders scientific successes made possible solid financial foundation year contained many highlights one strengthened sales increasing particularly stood without question group 's core earnings per share phase iii results presented higher previous year positive investigational medicine ocrelizumab multiple results attributed continuing strength sclerosis devastating disease current underlying business treatments vary benefit patients need better options potential improve pharmaceuticals division oncology situation particularly primary progressive immunology contributed significantly sales growth diversity drives form chronic disease effective following acquisition intermune treatments yet available particularly pleased report esbriet treatment fatal condition idiopathic oncology made significant advances pulmonary fibrosisis showing good growth cancer immunotherapy portfolio obtaining positive another highlight approval cotellic innovation outcomes bladder lung cancer pivotal trials combination zelboraf treatment lead candidate atezolizumab really advanced melanoma us europe encouraged improved sustained outcomes seeing cancer patients investing diagnostics division launch new cobas strongly promising treatment approach instruments marks achievement milestone studying investigational cancer automated integrated laboratory diagnostics severin schwan immunotherapy medicines nine new systems permit substantially higher test chief executive officer clinical trials throughput greater flexibility thus provide growth rates report constant exchange rates average increase excludes onetime benefit chf million tax related divestment filgrastim rights roche ceos shareholder letter ceos shareholder letter roche innovationdriven company important benefit healthcare providers also received approval fda improving health outcomes requires stakeholders constantly striving efficiency gains laboratory alecensa alectinib treatment specific public privateto work closely together employees play central role business contributed substantially diagnostics form lung cancer medicine created achieve sustainable solutions convinced division 's sales growth chugai approved japan roche together succeed improving quality success simultaneously developed companion diagnostic healthcare globally continuing incentivise roche also facilitating improving laboratory test identify patients could benefit true medical innovation work tissue sample staining central alecensa study correct diagnosis cancer roche every one employees current year expect sales grow low full automation excellent staining quality lung cancer one example disease committed medical innovation truly midsingle digit constant exchange rates core newly launched ventana system enables better understanding molecular processes makes difference patients innovation earnings per share targeted grow ahead pathologists work even greater safety cancer cells shed light many possible different driven company employees play central role sales constant exchange rates expect accuracy efficiency causes analysis molecular information success encouraging diversity essential increase dividend swiss francs already yielding insights important part fostering new ways thinking challenging continued make good progress research development purposes status quo finding new solutions remain confident roche 's longterm product pipeline five major approvals four targeted treatment patients roche innovation future science medicine progressing fda breakthrough therapy designations also means simplifying diagnostics patients talent management strategy focused giving unprecedented rate thanks new data medicines testament high level investing research bloodbased cancer tests employees opportunity develop professionally analysis techniques available us continue innovation achieving research also known liquid biopsies developing personally gaining experience different roles strong position develop new medicines development activities genentech cobas egfr mutation test v roche helping countries global company increasing diagnostic tests better patient care chugai various external alliances reflect broad minimise need intensive stressful surgical activities emerging markets diversity people range approaches ideas take example procedures collect tumour tissue samples experience becoming increasingly valuable early development phase results emicizumab acea medicine developed chugai meaningful use large amounts data would like thank employees prophylactic treatment people years older test results clinical practice set take personal contributions shareholders hemophilia awhich sufficiently promising even important role involved continued confidence roche us start pivotal phase iii programme pilot projects partnerships severin schwan foundation medicine flatiron health using chief executive officer highquality healthcare data advanced analytics improving health outcomes requires improve development medicines scientific basis treatment decisions stakeholderspublic privateto able realise plans work closely together achieve continue developing business sustainably important part strategy improve patient sustainable solutions access innovative tests medicines roche corporate executive committee corporate executive committee roche corporate executive committee left right dr michael varney head genentech research early development gred roland diggelmann coo division roche diagnostics dr stephan feldhaus head group communications silvia ayyoubi head group human resources dr alan hippe chief financial officer dr severin schwan ceo roche group dr sophie kornowskibonnet head roche partnering prof john c reed head roche pharma research early development pred osamu nagayama chairman ceo chugai dr gottlieb keller general counsel daniel oday coo division roche pharmaceuticals roche corporate executive committee december member enlarged corporate executive committee roche business review business review roche bu sine v ie w thanks strong business performance able enhance innovation capabilities deliver chf healthcare solutions make difference patients lives billion group sale roche business review business review roche roche reports strong results strong sales profit growth pharmaceuticals growth driven increasing demand oncology immunology group sales increased driven demand medicines along primarily pharmaceutical sales us strong uptake esbriet growth international strong demand immunodiagnostic products region driven key markets including profitability growth ahead sales diagnostics roche extended industry brazil china japan sales grew excluding onetime income chf million leading product portfolio seven test eight pharmaceuticals division sales rose driven avastin franchise sale filgrastim rights core instrument launches chf billion increase driven new lung cancer medicine alecensa operating profit increased constant exchange oncology portfolio led medicines rates basis core earnings per share strategic partnerships improve patient care avastin sales immunology franchise grew diagnostics sales grew chf billion chf higher january roche announced partnership driven strong uptake esbriet new asiapacific europe middle east flatiron health industry leader real medicine idiopathic pulmonary fibrosis well africa emea main contributors ifrs net income increased constant exchange world oncology data building collaboration higher sales actemraroactemra xolair sales sales latin america north rates declined swiss franc terms due foundation medicine begun pegasys declined due competition new america whilst sales japan stable major negative currency impact agreement another important milestone drive generation treatments whilst valcytecymevene major growth driver professional diagnostics leadership personalised healthcare high xeloda faced generic competition expected grew sales molecular diagnostics board directors recommended dividend quality healthcare data advanced analytics tissue diagnostics increased increase chf per share nonvoting equity improve development medicines regions contributed sales growth respectively diabetes care sales decreased due security subject approval annual general quality treatment decisions roche also particularly strong performance us continuing challenging market conditions meeting shareholders march acquired ariosa diagnostics signature diagnostics europe driven strong especially us roches th consecutive annual dividend increase capp medical kapa biosystems companies strong expertise technologies product approvals portfolio progress complement roches activities aimed building key figures made significant progress nextgeneration sequencing portfolio product pipeline investigational medicine chf millions chf millions change change cer chf ocrelizumab roche announced strong data outlook group sales relapsing primary progressive forms multiple roche expects sales grow low midsingle pharmaceuticals division sclerosis addition presented promising results digit constant exchange rates core earnings per diagnostics division lead investigational cancer immunotherapy share targeted grow ahead sales constant core operating profit medicine atezolizumab bladder lung cancer exchange rates roche expects increase excluding filgrastim roche also received eu us approval cotellic dividend swiss francs core eps diluted chf plus zelboraf treat metastatic melanoma us excluding filgrastim approval cancer medicine alecensa ifrs net income specific form lung cancer growth rates report constant exchange rates cer average asiapacific eemea eastern europe middle east africa latin america canada others excluding onetime benefit chf million tax related divestment filgrastim rights ifrs international financial reporting standards roche business review business review roche embracing dynamic market environment adjuvant therapy herceptin helps prevent breast ultimate goal developing reliable tests cancer patients developing metastases based biomarkers central personalised healthcare strategy focused innovation herceptin introduced adjuvant setting gamechanging arena molecular information driven rd opening doors medical innovation roche recently entered several strategic partnerships focused genome sequencing matter market evolves remain fully bactrim medicine still used treating analysis including foundation medicine committed central principles putting bacterial infections medicine andme human longevity harnessing patient centre everything focusing administered two billion people worldwide genome sequencing data roche hoping gain healthcare innovation working closely continues important impact number women prevented developing metastases deeper insights disease biology enable external partners developing regions incidence herpositive metastatic breast cancer without identification new pathways biomarkers herceptin targets used improve drug discovery primary contribution healthcare developing treated modern stateoftheart therapy develop better treatments improve patient care innovative medicines tests improve hivaids chronic infection today almost patients five major eu countries prevented outlook patients next three years mortality rate dropped roche developing metastases effect adjuvant partnering critical part rd strategy planning launches eight new medicines played important role developing herceptin given main treatment usually surgery healthcare industry vast majority coming labs aimed surpassing standards innovative diagnostic tests enabled innovation happens outside single company care personalised treatment strategies breakthrough also proud making progress outside truly innovative research likely flourish medicines like firstever protease inhibitor cancer difficulttotreat diseases companies strong inhouse capabilities market leader immunodiagnostics pcr multiple sclerosis ms currently limited diverse extensive network partnerships tissue diagnostics increasing offerings leader oncology roche made important treatment options debilitating disease sequencing also wellplaced deliver fully contributions significantly lowering cancer mor announced strong latestage clinical study roche one first healthcare companies integrated testing solutions tality rates past years late results potential significantly recognise importance external innovation roches biopharmaceutical herceptin represented improve way ms treated currently running partnerships lasting commitment improving lives major step forward treatment particularly across group consistently grown research aggressive form breast cancer years roche molecular information enhancing rd decisions groundbreaking innovation past nearly brought eleven cancer medicines proven past years roche optimised roches rd productivity years proud contributed survival benefit patients cooperation pharmaceuticals major advances healthcare introduced diagnostics divisions translating scientific progress however battle cancer new tests targeted medicines shown treatment especially difficult advanced impressive outcomes already example roche medicines included stages cancer metastasised remain studies testing investigational cancer medicines fully committed continuing raise bar essential medicines list cancer patient outcomes see great potential although rd processes different two cancer immunotherapy divisions share research facilities technologies combination treatments discoveries working together internal projects roche industry early stages drug discovery biomarkers roches rd success rate industry average provide critical information disease development based kmr rd general metrics data diagnostics involved early research projects boston healthcare value innovation hivaids therapy roche business review business review roche emerging markets account nearly expanding access emerging markets johannesburg provide handson certified committed working stakeholders inequalities access healthcare increasing training courses facility boasts five selfcontained find innovative pricing solutions moving away growth coming years tremendous opportunity commitment laboratories latest technological tools volumebased valuebased many pilot programmes overcome access barriers diagnostic tests chemistry hematology molecular biology tissue shown solutions give payers medicines around world diagnostics sequencing healthcare authorities flexibility comes reimbursement decisions compliance requirement roche roche strongly believe critical new patients receiving donated herceptin china basis license operate key uncover root causes country country able pap increasing employee diversity implementing mission improving patients lives implement solutions make meaningful estimate nearly growth difference ground also established come emerging markets coming years seizing right opportunities wide range policies programmes partnerships want make sure people right experience risktaking especially business prerequisite adapted needs different local situations committed cultivating diverse talent innovation growth improved business performance pipeline help people company excel sustainable returns key effectively manage established patient assistance everchanging business environment risk reduce negative uncertainties transform programme pap cancer foundation challenges business opportunities china patient groups led compliance integral part culture significant increase access breast cancer whether approach science risk organisation place provides medicine herceptin however always pap implemented business partner society committed structure support guidance proactively access medicines also shortages high ethical social standards integrity assess risks opportunities caught equipment health education address number patients herceptin significantly increased fundamental part business roche unaware unprepared inventory major group lack trained diagnostic workers laboratory implementation roches pap china wide risks compiled analysed annual capacity south africa run scientific campus transparency clinical trial information basis analysis published group risk although access barriers healthcare complex governance interactions key stakeholder report distributed review corporate multifaceted pricing one major areas groups regular audits internal manufacturing executive committee board directors patients access focus many stakeholders majority processes systems go beyond legal help shape strategic decisions markets price medicine unitbased regulatory requirements herceptin roches patient undifferentiated driven volume therapy used assistance programme china roche diagnostics diagnostics roche iag nostic market leader vitro diagnostics business provide largest number test results empowering physicians patients make informed health decisions billion te st conducted roche instruments worldwide roche diagnostics diagnostics roche ur tests provide critical information faster precise decisionmaking medical care research development commercially available vitro diagnostic ivd better prediction therapy outcomes tests increasingly used healthcare providers advances science driving rapidly growing screen diagnose monitor therapies tests understanding disease biology patient responses critical even lifesaving emergency situations therapy new insights help answer critical immunodiagnostic tests example help physi clinical questions guiding treatment decisions cians make onthespot treatment decisions ensure effective safe therapies also person may may stroke getting better collecting analysing molecular information thanks new technologies virology increasing demand deep gene sequencing molecular information enables cervical cancer screening diagnostic tests physicians better predict outcome therapeutic noninvasive harmony prenatal test critically interventions optimise treatment strategies important pregnant women providing accurate information without risk baby understanding lung cancer root drivers mother meanwhile increasing number great example demonstrates benefit people diabetes blood glucose meters molecular information dozen different lancing devices insulin delivery systems mutations cause disease potentially requiring important tools manage condition effectively different therapeutic interventions described merely cancer specific organ described molecular level scientific information helps physicians pinpointing mutation causing lung cancer physicians make better treatment decisions make better treatment decisions ultimately improve outcomes patients ultimately result better outcomes patients roche diagnostics diagnostics roche diagnostics deliver strong growth meeting different market requirements increase diagnostics annual sales contributing overall performance diagnostics sales increased continued good growth regions roche group chf billion asiapacific europe especially asiapacific sustained strong middle east africa emea main sales increases china contributors growth sales china latin america recorded sales growth sales increased molecular diagnostics driven sales north america increased japan growth underlying molecular business sales stable sequencing business major contributions sales growth came virology hpv tissue diagnostics increased sales driven markets diabetes business challenging growth professional diagnostics driven screening sales grew strongly emea growth advanced staining portfolio diabetes care sales declined due immunodiagnostics clinical chemistry japan decline sales resulted nonrenewal includes immunohistochemistry reagents continuing challenging market conditions coagulation monitoring businesses tender blood screening largest growth contributions came north blood glucose monitoring portfolio especially america emea us sales blood glucose meter accuchek mobile grew sales accuchek performa several major tenders secured remained stable accuchek aviva declined sales netherlands roche awarded fiveyear lancing devices increased growth partially sales top selling products chf millions contract national institute public health compensated impact phasing older environment implementation products insulin delivery systems business grew cobas hpv test firstline primary screening test driven infusion systems newly national cervical cancer screening programme launched accuchek insight nextgeneration insulin delivery system combining insulin pump additionally major blood screening tender blood glucose meter contracts thailand germany united kingdom spain well significant competitive tenders sales increased regions latin america virology united kingdom france germany asiapacific decreased north america emea tests run nextgeneration japan overall business efficiencies gained accuchek aviva cobas cobas systems implementation specific measures initiated cobas e connect cobas c ventana cobas streamline processes reduce costs immunodiagnostics diabetes care clinical chemistry tissue diagnostics virology growth rates report constant exchange rate average roche diagnostics diagnostics roche transforming laboratory practice automation connectivity using highquality hardware interaction allow better quality control sample preparation ultimately leads reliable results medical health testing going dramatic doubling already marketleading throughput paradigm shift one hand new testing tech current instrument results nologies support large centralised laboratories per hour key feature cobas c new fully automated connected workflow conducted slides providing medically relevant results constant instrument used laboratories analysis launch elecsys htlviii immunoassay laboratories countries stained increase efficiency hand pointof hbac levels blood samples people completes blood screening portfolio serology ventana system reviewed care testing gaining importance ensuring diabetes cobas c essential tool provides unique ability combine pre pathologists excellent results immediate precise decisionmaking spot healthcare providers coping everincreasing analytics nucleic acid testing serology testing offering increased testing capacity highest levels number people condition automated blood screening cobas rapid advance science resulting automation connected workflows well cobas systems connected workflow need molecular information laboratories laboratory information systems instruments another key milestone fda approved making combination first kind increasingly utilise number technologies launched support customers cobas cobas systems cobas market products well received markets parallel including immunodiagnostics clinical transforming businesses hbv cobas hcv cobas hiv viral load tests chemistry tissue analysis pcrbased technologies fully automated systems offer fastest time also launched ventana system gene sequencing marketleading example cobas v automated workflow results highest throughput longest walk globally fully automated hematoxylin eosin portfolio immunodiagnostics pcr tissue series fullyautomated system covering away time available among automated molecular tissue staining system enhances patient analysis progress made sequencing operational preanalytical integrated post platforms providing laboratories improved safety avoiding crosscontamination produces last two years forefront analytical steps laboratory well sample operating efficiency flexibility adapt exceptional staining quality supporting laboratories businesses transport technology enables full connectivity changing testing needs analytical archiving devices designed system improves workflow eliminating highthroughput laboratories capacity new tests next generation viral load need manually mix reagents global test samples per hour tests clinicians use manage treatment people hepatitis b hepatitis c virus well hiv us approval follows launch diabetes new cobas c doubles systems tests countries accepting ce mark throughput results per hour wwwrochecomproducts conformit europenne symbol free marketability european economic area roche diagnostics diagnostics roche modern targeted therapies diseasecausing mutations unknown egfr met splice site alk fusions met amplification kras braf broadening portfolio nras pikca ros fusions akt kifbret mapk multiple tests connected systems many test approvals launches accuchek connect fully integrated diagnostic multiple genetic mutations may cause nonsmall cell lung cancer past variations could distinguished today molecular information supports year broadened industryleading product system app online portal fda treatment decisions effective targeted therapies portfolio new elecsys htlviii immunoassay approved bolus calculator improve diabetes self diagnostic test help detect antibodies management launched us human tlymphotropic virus ii infections donated blood routine diagnostic samples fda granted clinical laboratory improvement amendments clia waiver assists clinicians making timely treatment september launched cobas egfr designed needs blood centres clinical cobas strep test use cobas liat system decisions aids prevention mutation test v first oncology test utilises laboratories reliable efficient detection streptococcus responsible wide range infection healthcare settings either plasma tumour tissue sample test microorganism test enhances blood invasive noninvasive infections identifies mutations epidermal growth screening portfolio serology testing builds first cliawaived pcr test detect strep cobas hsv herpes simplex virus factor receptor egfr gene vitro current offering comprehensive throat swab specimens test direct detection differentiation diagnostic market test also used blood screening hsv hsv dna symptomatic patients aid selecting eligible patients nonsmall cobas influenza ab test use cobas liat received fda k clearance dualtarget cell lung cancer nsclc therapy egfr improved cardiac pointofcare troponin test system also received clia waiver easytouse detection automation test provides tyrosine kinase inhibitor cobas h system available countries tests used nontraditional testing sites laboratories capability report accepting ce mark allows healthcare professionals physician offices emergency rooms results significantly less time traditional targeted therapies become available rapidly identify patients suspected acute healthcare facilities provide results point methods provides simplified workflow critical provide oncologists innovative myocardial infarction also termed heart attack care sample handling laboratory molecular testing methods make easier greater accuracy low troponin concentration patients get tested without subject surgery handheld pointofcare diagnostic system cobas hiv hbv hcv hcv genotyping risks tumour tissue availability used places heart attack patients often assays launched countries accepting seen first ambulance emergency room ce mark new molecular diagnostic assays primary caregeneral practitioners office increase available menu cobas system improving efficiency flexibility allow laboratories deliver results rapid new cancer test allows clinical decisions detection cancer blood fda provided clearance cobas cdiff test detect clostridium difficile c difficile stool patients sick invasive specimens test provides accurate information tissue biopsy davenport l egfr testing done lung cancer patients medscape medical news roche diagnostics diagnostics roche personal perspective liquid scientist honestly say dream job biopsy test addition complementing tissue biopsy ability detect traces detecting cancer liquid biopsy enormous broader diagnostic potential colleague lin wu hypothesised could use technology monitor patient response treatment cancer without surgery development drug resistance clinical results confirmed hypothesis thrill whole team potential personalise cancer therapy already walter koch phd head research hiv hepatitis patients many occasions calibre scientific research roche molecular diagnostics conducted colleagues makes proud building cobas egfr mutation test v new era cancer expanding application technology accuracy egfr activating colorectal breast types cancer resistance mutations present nonsmall cell diagnostics lung cancer patients also exploring liquid biopsies actionable gene fusions smaller genetic sequences liquid biopsy test runs cobas microribonucleic acidsopening exciting new interested cancer since started diagnostic platform found many community horizons terms detect treat working lab technician age today hospitals means faster results also means monitor cancer head research roche molecular diagnostics greater access targeted therapies patients comprising talented people scientist often tested egfr mutations even honestly say dream job although developed countries due lack tissue test longer opportunity work lab test positive liquid biopsy patients part team pushing new frontiers start targeted therapy roches tarceva science take insights translate fact tarceva team first suggested diagnostics help better detect cancer supported development liquid biopsy test serious diseases illustrates synergies pharmaceuticals diagnostics one roof roche good example cobas egfr mutation test v detects dna nonsmall cell lung cancer liquid biopsy technology offers many benefits plasmathe yellowish liquid remains patients current practices detecting cancer blood cells removed blood eight based microscopic examination tumour tissue hours little ml plasma detect acquired surgery invasive biopsy patients sense excitement learning something new simply sick undergo procedures every day sharing success team roche pharmaceuticals pharmaceuticals roche phar mace utical roche provides medicines truly improve patients lives recently approved combination therapy cotellic plus zelboraf advanced melanoma roche brings another option patients lifethreatening hardtotreat disease million patie nt treated one roches top selling medicines roche pharmaceuticals pharmaceuticals roche w e focus disease areas high unmet medical need expertise make real difference patients world leader oncology medicines nonsmall cell lung cancer nsclc data helped revolutionise treatment many types presented american society clinical cancer take avastin example designed target oncology demonstrated importance angiogenesisa process new blood vessels understanding immune biology cancer treatment formed help tumour growavastin also presented new pivotal data gazyva become pillar cancer treatment today avastin gazyvaro showed medicine could approved treat seven different types cancer improve outcomes patients difficult totreat indolent nonhodgkin lymphoma inhl medicines targeting herpositive breast cancer herceptin perjeta kadcyla allow people received marketing approvals new targeted advanced disease live longer therapies including cotellic combination earlystage cancer chance sustained remission zelboraf advanced melanoma alecensa mabtherarituxan first monoclonal antibody specific type lung cancer believe future remains widely used medicine treat cancer treatment lies combination therapies common forms blood cancer avastin targeted treatments cancer immunotherapy herceptin mabtherarituxan played role treatment seven million patients beyond oncology esbriet new medicine treat idiopathic gained important insights next pulmonary fibrosis fatal lung disease already wave cancer therapy recognition making big difference patients first year pipeline innovation exciting data key approvals market also presented data suggested fda granted second breakthrough therapy continuing treatment esbriet early designation lead cancer immunotherapy hospitalisation may help slow disease progression candidate atezolizumab time pdl positive also announced important new data treatment multiple sclerosis ms three positive jeffrey schwartz pictured right latestage clinical studies investigational ms medicine ocrelizumab confirmed hypothesis participated one cancer b cells central pathogenesis disease submit data regulatory authorities immunotherapy clinical trials marketing approval roche pharmaceuticals pharmaceuticals roche pharmaceuticals deliver strong growth driven oncology immunology increase pharmaceuticals annual sales driving roche groups overall pharmaceuticals sales increased japan kadcyla sales driven primarily performance chf billion key drivers included herceptin demand europe perjeta kadcyla combined positive breast cancer herpositive metastatic mabtherarituxan common forms blood gastric cancer herceptin herceptin sales cancers including nhl follicular lymphoma grew strongly especially us longer chronic lymphocytic leukemia rheumatoid duration treatment combination perjeta arthritis certain types vasculitis performed well avastin advanced colorectal breast lung actemraroactemra rheumatoid early advanced breast cancer strong demand sales growth driven primarily strong demand kidney cervical ovarian cancer glioblastoma arthritis systemic juvenile idiopathic arthritis seen international region notably us demand continued increase type brain tumour posted strong sales growth polyarticular juvenile idiopathic arthritis recorded china brazil perjeta also saw strong oncology immunology sales increased increased sales seen across regions due strong growth sales increased across regions driven growth particularly us europe international region led increasing demand rising demand ovarian colorectal lung cervical strong demand subcutaneous formulation approved use surgery earlystage brazil china japan cancer following launches europe emerging particularly us europe aggressive breast cancer also good growth markets strong growth seen us june fda granted breakthrough therapy international region particularly designation actemra systemic sclerosis china uptake colorectal cancer key growthdriving products chf millions new lung cancer indication fuelled growth japan esbriet chf million idiopathic pulmonary growth driven demand breast fibrosis ipf fatal lung disease continued lung cancer strong uptake approved fda swissmedic sales reached chf million us lucentis us eye conditions wet age chf million europe chf million related macular degeneration wamd macular edema international region september additional following retinal vein occlusion rvo diabetic data presented pooled analysis three macular edema dme impacted competitive phase iii studies suggested reduction pressure wamd dme segments treatmentemergent risk death ipf patients february fda approved lucentis taking esbriet two years additional indication diabetic retinopathy people avastin herceptin perjeta kadcyla esbriet dme oncology oncology oncology oncology immunology growth rates report constant exchange rates average asiapacific eemea eastern europe middle east africa latin america canada others nathan sj et al effect pirfenidone treatmentemergent te allcause mortality acm patients idiopathic pulmonary fibrosis ipf pooled data analysis ascend capacity roche pharmaceuticals pharmaceuticals roche significant breakthroughs advancing patient care fda granted four breakthrough therapy fda also granted priority review venetoclax major regulatory milestones designations medicines designation investigational medicine developed helps accelerate development review partnership abbvie patients hard product project description medicines intended treat serious diseases may totreat type chronic leukemia followed fda breakthrough atezolizumab pdl positive nsclc demonstrate substantial improvement existing second breakthrough therapy designation therapy designation emicizumab ace hemophilia factor viii inhibitors therapies total received designation venetoclax combination mabtherarituxan actemraroactemra systemic sclerosis times testament commitment relapsed refractory cll third aml venetoclax p deletion relapsedrefractory chronic lymphocytic leukemia innovation acute myeloid leukemia aml targeted cancer therapy approvals mabtherarituxan relapsed refractory cll part breakthrough therapy designation fda european commission filing avastin tarceva egfr mutationpositive nsclc eu submitted data fda lead investigational approved cotellic combination zelboraf avastin advanced cervical cancer japan cancer immunotherapy medicine atezolizumab treatment people braf mutation gazyvagazyvaro rituximabrefractory indolent nonhodgkin lymphoma us eu treatment people metastatic bladder cancer positive metastatic melanoma updated pivotal data approval alecensa secondline alkpositive nsclc us also plan submit data fda showed combination helped people live avastin advanced cervical cancer eu breakthrough therapy designation atezolizumab significantly longer median two years lucentis diabetic retinopathy diabetic macular edema us treatment people whose nsclc expresses compared zelboraf alone perjeta early herpositive breast cancer neoadjuvant presurgical treatment eu pdl whose disease worsened cotellic zelboraf brafpositive metastatic melanoma us eu standard treatments either submitted plan fda also approved alecensa people submit data cancer types global health advanced alkpositive nsclc whose disease authorities also presented promising data progressed following treatment crizotinib atezolizumab specific types advanced breast second approval medicine last three years fda granted cancer melanoma medical conferences created chugai member roche group approved japan also submitted breakthrough therapy designation american society hematology presented marketing authorisation application ema followup results pivotal study people indications roche medicines inhl relapsed within six months targeted therapies approved treatment mabtherarituxanbased companion diagnostics building leadership regimen subgroup analysis people personalised healthcare patients respond follicular lymphoma common type inhl medicine way using diagnostic treatment gazyvagazyvaro plus bendamustine test possible better understand disease provided significantly greater depth remission well patient may respond treatment sales end induction compared bendamustine alone products companion test label represent fda granted breakthrough therapy designation venetoclax combination mabtherarituxan treatment people relapsed pivotal study data submitted approval pharmaceuticals division sales refractory chronic lymphocytic leukemia cll january venetoclax acute myeloid leukemia aml january roche pharmaceuticals pharmaceuticals roche approximately people approximately people north america ms europe ms promising results multiple sclerosis potential new treatment option disease central nervous system multiple confirming central role b cells sclerosis ms chronic disease decade scientists pioneered immune system abnormally attacks insulation concept selectively targeting component ms prevalence highest countries furthest approximately people support around nerve cells brain immune system cdpositive b cell may spinal cord optic nerves causing inflammation effective therapeutic approach people ms equator australia ms damage people diagnosed disease prime lives whilst concept widely accepted years age ms affects approximately million medical community scientists conducted mapping incidence ms around world people worldwide indepth research followed development programmes longterm view commitment patients relapsing disease common development ocrelizumab humanised form attacks periods time symptoms monoclonal antibody targeted specifically flare primary progressive form cdexpressing b cells hypothesis b cells progression clinical disability compared medicines based broad expertise affect ms patients suffer disability central pathogenesis relapsing ms placebo safety profile similar placebo developing number innovative medicines continuously worsens onset confirmed neuroscience disease typically without distinct relapses ocrelizumab first investigational medicine periods remission compelling study results show positive study results primary progressive one strongest pipelines industry data two phase iii studies opera relapsing forms ms affects approximately developing medicines range serious cure ms various treatment opera ii demonstrated clinically meaningful people ms time diagnosis neurological diseases beyond ms including approaches varying degrees benefit benefit ocrelizumab people relapsing ms submit ocrelizumab data global regulatory alzheimers disease autism spinal muscular atrophy patients presented results three pivotal studies ocrelizumab compared authorities forms ms early depression parkinsons disease syndrome phase iii clinical studies investigational approved standardofcare interferon see details medicine ocrelizumab ms provide hope showed treatment ocrelizumab led results build deep understanding new paradigm treatment significant reductions frequency ms immunology developing novel antibodybased relapses progression clinical disability loss physical abilities number lesions ms leading cause nontraumatic brain safety profile similar standard care disability young people usually another phase iii study oratorio assessed rebif registered trademark merck kgaa emd serono inc multiple sclerosis international federation atlas ms striking years age ocrelizumab primary progressive ms debilitating national institute neurological disorders stroke multiple sclerosis hope research simpson et al latitude form disease demonstrated reduction significantly associated prevalence multiple sclerosis metaanalysis j neurol neurosurg psychiatry roche pharmaceuticals pharmaceuticals roche personal perspective teamwork perseverance enabled us succeed convinced whilst team moved ahead right thing ocrelizumab formed tightknit subteam develop comparator placebo first broke active comparator component parts design comparator placebo leveraged external ms patients manufacturing network produce placebo syringes meet strict requirements human injection drug faced many obstacles merciless ticking rita wong head us global biologics clock teamwork perseverance enabled us succeed producing comparator manufacturing science technology drug product placebo time convinced right thing ms patients set high bar test ocrelizumab allowed us produce compelling doubleblind comparative clinical data context well roche clinicians wanted increase scientific characterised active comparator rigour phase iii trials comparing design ocrelizumab standardofcare medicine took current position kept approved treatment ms arms eye clinical trials october positive doubleblinded meaning neither patients phase iii results ocrelizumab ms released intensely curious person one clinicians knew whether received placebo hard work worth favourite words natural investigational medicine become scientist inquisitiveness helped almost decade working ocrelizumab technical development team supplied investigational medicine studied patients materials clinical trials first study multiple sclerosis msa disease strikes arm scaled production ocrelizumab young adults prime lives produced placebo formulation identical appearance administration intravenous infusion joined genentech right college hired formulation development group second arm purchased drug simply stated ensure active ingredient standardofcare medicine approved treatment medicines remains stable usable began working ms could develop placebo looked ocrelizumab formulation four years like marketed comparator drug came later appointed technical development leader syringe multiple doses different presentations prior phase iii trials ms never done roche clinical trial design allowed us show clear benefits six months start ms trials ms patients roche innovation innovation roche innovation broad portfolio new molecules address high unmet medical needs forefront transforming science new therapies new molecular entities clinical development roche innovation innovation roche lmost decade ago transformed rd activities interconnecting pharmaceuticals diagnostics research increasing investment external innovation approach fostered scientific diversity positioned develop nextgeneration tests creativity needed develop powerful tests medicines medicines delivering today industry research early development carried tomorrow means years value early four organisations genentech research early entry personalised healthcare seen development gred roche pharma research broad deep pipeline includes growing early development pred chugai pharmaceutical number targeted drug candidates companion co ltd japan member roche group diagnostics today seeing new treatment diagnostics division also winwin approaches combining therapies attack partnerships alliances external illness different angles hold great promise companies institutes turn cancer complex diseases chronic conditions people live triggered explosion scientific insights well molecular genetic data experts forefront current biological revolution additional disciplines collaborating closely researchers thinking diseases today roche master challenges complex immune system fundamental molecular diseases pose development teams compounds cellular level looking harness successfully developed gred pred chugai vast increase molecular information next partners progress global latestage important step efforts develop even better development organisation personalised treatment solutions core rd investments roche group pharmaceuticals diagnostics chf bn chf bn chf bn sales sales sales growth rates report constant exchange rates average roche innovation innovation roche transforming care new treatments new era tackling cancer cancerimmunity cycle learned tumours years developing disrupt cycle disabling hiding medicines improved even redefined coopting immune response several points science better patient care oncology treatment believe advances cancer along way goal cancer immunotherapy therapy progress dramatically research identify understand counteract emerging field cancer immunotherapy based tumours ability suppress immune response understanding biology cancer immune system molecular levels cancer scientists focused inhibiting diverse know diagnosis two people therapies last two decades recently immunotherapy aims provide patient mechanisms tumour use sabotage may stem completely different genetic causes investing heavily emerging field tailored treatment powers immune system also stimulating immune meaningfully diseases fact cancer immunotherapy made inroads immune system fight particular cancer response cancer rd programme single disease worldclass scientists across understanding multifaceted biology includes cancer immunotherapy roche group uncovering intricate details immune response individuals cancer view today investing ever bring candidates target one steps cancer disease biology root molecular causes biological diversity adaptability cancers personalised cancer immunotherapy physicians immunity cycle example overexpression cancer inflammation neurological disorders believe combination therapy designed according growing toolkit targeted medicines protein programmed death ligand pdl cancer rheumatoid arthritis complex diseases specificity disease presentation play cancers along diagnostic tests immune cells block last stages time diving deeper human important role battling cancer accurately predict likely respond cancerimmunity cycle inhibiting pdl biology unlock mysteries immune atezolizumab thwarts disruption allows systemhow fights surrenders overwhelmed gamechanging arena molecular information harnessing immune system fight cancer immune cells attack tumour interacts enemy cellular battlefield driven rd requires us update every area cancer cells use cellular camouflage avoid product development basic research target attacked immune system long time new drug candidates offer promise diverse insights driving groundbreaking identification molecule design clinical research unclear cancer cells going undetected atezolizumab investigational antibody designed discoveries transforming medicine identification relevant biomarkers development scientists including experts across roche fight tumours blocking pdl protein practiced instance pioneering companion tests addition recasting group unravelling mystery cancer pdl produced surface tumour concept confirmed hypothesis longstanding model clinical studies bring evades immune system starts grows immune cells believed act stop sign b cells central pathogenesis multiple effective treatments patients faster also spreads using knowledge develop blocks immune cells recognising attacking sclerosis announced exciting results learning standardise validate cull best medicines harness bodys immune system destroying cancer cells dozen latestage clinical studies submitting use astounding volume scientific realworld fight cancer different tumour types hijacked pdl data regulatory authorities approval data generated every day increasingly pd interaction atezolizumab removes cellular critical decisions made roche regulators payers data number roche clinical studies camouflage tumours allowing immune proud legacy paradigmshifting ultimately providers patients presented last months reveal cancer cells attack cancer innovations including treatments diseases immunotherapies show extraordinary promise central nervous system powerful anti whilst main focus oncology inflammation treatments previously failed treated bladder cancer phase ii imvigor study infectives well cancer immunology neuroscience infectious diseases advanced cancer immunotherapies showed atezolizumab shrank tumours ophthalmology open areas patients terminal cancers lived people metastatic urothelial carcinoma muc make real difference patients extensively longer periods time compared benefit whose disease medium high levels pdl diving deeper human biology helped make progress treatment many classical treatment expression worsened initial treatment diseases years ago viable results assessed people understand immune system treatment options however tremendous unmet targeting cancerimmunity cycle responded atezolizumab continued respond medical need remains immune system protects body cancer engage cancer understand multistep roche innovation innovation roche release cancer cell antigens cancer antigen presentation killing cancer cells priming activation cancer two phase ii studies evaluated atezolizumab people believe diagnostic information immunity advanced nonsmall cell lung cancer nsclc important physicians patients cycle randomised phase ii study poplar showed opportunity incorporate available information people recurrent nsclc whose tumours treatment decisions differentiating expressed medium high levels pdl survived patients likely benefit monotherapy statistically significant months longer perhaps considered migration cells tumours people received docetaxel chemotherapy alternative treatment strategiesfor example recognition cancer cells cancer immunotherapy combination clinical trial separate pivotal singlearm phase ii study birch important consideration making showed drug candidate shrank tumours treatment decision people whose disease progressed infiltration cells tumours prior medicines also expressed highest ways target cancerimmunity cycle levels pdl thought tumours able evade recognition immune system atezolizumab studies median counter tumours ability hide immune cancerimmunity cycle survival yet reached adverse system developing specific diagnostics illustration immune system recognises kills cancer cell one patient cycle fail one number points events consistent observed understand type tumour best deliver adapted chen mellman previous studies appropriate treatment strategy along various steps cancerimmunity cycle us fda granted breakthrough therapy scientists also looking differences designation atezolizumab treatment expression patterns immunoregulatory molecules muc nsclc respectively people respond treatment versus ultimate goal bring benefits promise production immunosuppressive metabolites ido aim identify patients cancer immunotherapy people blocks proliferation effector cells whilst companion diagnostics guide therapy decisions may benefit specific combination therapy greatest need new treatment options across promotes generation regulatory cells keeping personalised healthcare strategy monotherapy identify new targets roche group scientists identified broad counteract fighting activity effector cells atezolizumab studies include evaluation drug discovery pipeline compounds target different cancer investigational immunohistochemistry test developed immunity checkpoints along cycle furthermore ido expressing apcs become pro inhouse uses specific antibody measure research indicates patients whose tumours tolerogenic unable prime effective immune pdl expression tumour cells inflamed show active invasion immune among strategies employed tumours block response presentation cancer proteins infiltrating immune cells cells higher response rate atezolizumab cell activity ido protein induction ido antigens lymph nodes tumour patients noninflamed tumours lack expression unregulated tumour cells andor microenvironment result ido expression invasion antigenpresenting cells apcs situ helps tumour evade immune system ongoing planned depletion extracellular tryptophan blocks effective antitumour immune response working find new ways deepen phase iii studies atezolizumab treatment responses atezolizumab inflamed tumours turn noninflamed tumours across several kinds lung kidney inflamed tumours combination therapies atezolizumab potentially trigger response breast bladder cancer chen ds mellman oncology meets immunology cancerimmunity cycle immunity roche innovation innovation roche atezolizumab foundation cancer immunotherapy portfolio multiple combinations multiple combinations activating additional antagonists signals immune cells divide proceed performing inhouse partnered attack ilv designed favour immunestimulatory research develop compounds target immunesuppressive cells creating tumour ido tdo tryptophandioxygenase hostile milieu due specific targeting antibody chemotherapy another protein like ido involved tryptophan expected act strongly tumour degradation firstinclass dual idotdo inhibitor host organs leading reduced cytokinemediated developed curadev pharma private toxicities seen current il therapies limited also research agreement launched portfolio immunotherapy portfolio newlink genetics corporation discovery supporting immune system alecensa avastin cotellic gazyvagazyvaro acd acdcd tdb aceailv nextgeneration idotdo compounds small order help immune system identify herceptin kadcyla mabtherarituxan aox acsfr humab afapilv fp molecule idoinhibitor rggdc engage tumour cells designed unique perjeta tarceva zelboraf atezolizumab ceatcb idoi indolamine dioxygenase ido checkpoint form engineered cell bispecific antibody molecules clinic projects pipeline clinical trials inhibitor developed collaboration redirect cells tumour cells newlink genetics currently clinical specific manner cell bispecific antibody development another ido inhibitor incb binds simultaneously target tumour cells developed collaboration incyte including cea cd target cells separately begun investigating newly provokes cell activation cell proliferation example working several types cancer suppressing cells promoting tumour discovered immune receptor target known cell infiltration destruction tumours vaccines might trigger tumourspecific cell growth formation cancerinduced blood tigit cell immunoreceptor ig itim rg bispecific antibody targets cea found response patients responses vessels combination studies patients also domains may play role finetuning surface colorectal gastric cancers occurred spontaneously begun antiox antibody pd response pancreas lung breast cancers rg ido inhibitor rg rg phase clinical dive deeper complex biology along inhibiting tumours ability sabotage development tumours immune system increasingly cancer immunotherapies immune system exploring pathways believe combination treatment approaches may research development nine compounds activate immune response apcs also testing antibody rg moxr hold greatest promise cancer patients currently tested clinical studies multiple highly effective stimulators cells activated designed stimulate immune response activating currently numerous studies underway internally combinations investigation comprehensive antibodies engineered bind cd surface ox signalling pathway tumour tissue partners test atezolizumab combination cancer immunotherapy programme covers total protein therefore boosting apcs represents eliminates immunosuppressive regulatory cells immunomodulators trials underway lung kidney breast additional tactic augment number active lymph nodes soon apcs transport leading tumourtargeted therapies avastin cancer ultimately expect cancer immunotherapy effector cells cd agonist rg activates tumour antigens stimulates growth cells zelboraf spawn new era oncology development apcs engulfed tumour antigens therefore battle tumour cells rg tested phase therapies transform deadly cancers chronic stimulating tumour reactive cells rg clinical trials single agent combination one phase clinical trial initiated combines diseases patients live long time developed combination immuno atezolizumab drug candidate holds promise atezolizumab emactuzumab rg antibody therapeutic antibodies including atezolizumab treating several types cancer colonystimulating factor receptor nine new molecular entities involved production tumourassociated using cytokine fusion protein another strategy cancer vaccines immunotherapy combinations macrophages tams emactuzumab blocks clinical studies cancer immunotherapy mobilise cells tumour antibody researchers exploring innovative approaches activity survival tams preventing rg binds carcinoembryonicantigen cea enable immune response tumour protein found surface many cancers specific effector cells found either carries molecule called interleukin variant ilv tumour tissue immune environment roche innovation innovation roche personal perspective experiences cancer helps special empathise patients opportunity regained weight lost importantly able read play two small children impactas year later started clinical study pleasure meeting jeff expressed interest meeting us doctor special experience knew scientist physician data point clinical study jeffs story extremely gratifying many levels continues well today results like give oncologists incredible sense fulfilment purpose dan chen md phd cancer immunotherapy franchise head patients respond well jeff therapy global product development oncology addressed particular pathway immune system known pdl many opportunities cancer cells camouflage escape immune system immune response however leading work helped focus mind spirit understanding immune system works year half never missed day cancer rapidly developing even newer ways fighting cancer work treatment tough help immune system recognise fight cancer times due location tumour werent able get biopsy also come grips new insights occurring cancer immunotherapy scientist always fascinated uncertainty whether going live die every day amazing time field potential harnessing bodys immune job special opportunity impact system fight cancer particularly encouraged today investigational cancer scientist physician progress making area roche immunotherapies seen cases unlike others realising potential years medical practice patients clearly nearing end recalled regaining trained medical oncologist seen much former life continue well many patients fight bravely cancer desperate times doctor one patient jeff schwartz counsellor often friend watched diagnosed stage iv sarcomatoid renal cell lose battle carcinoma february metastases already spread throughout body told kidney personal glimpse specialist six months live difficult journey fight informed mri back showed december jeff started clinical trial twocentimetre tumour spine tumour one cancer immunotherapies time crushed nerves spine putting pain started treatment could barely get bed pleasure meet jeff expressed interest meeting excruciating frightened children study jeff responded well treatment us doctor oncologist omid hamid roche innovation innovation roche positive pipeline news flow prostate cancer factor viii inhibitors well trial pediatric ipatasertib rg akt inhibitor developed patients less years old hemophilia partnership array biopharma reached efficacy inhibitors factor viii strong data clinical studies safety endpoints combined abiraterone phase ii trial patients castrationresistant neuroscience prostate cancer previously treated docetaxel number investigational medicines chemotherapy activation pikakt pathway clinical development neurological disorders associated poor prognosis may lead including multiple sclerosis ms alzheimers disease gain greater understanding tumour idasanutlin currently studied phase iii resistance standardofcare therapies ipatasertib ad parkinsons disease pd spinal muscular biology immune function cancer divided trial relapsedrefractory acute myeloid leukemia blocks signalling akt combined atrophy sma syndrome autism spectrum ever specific subtypes defined rr aml idasanutlin firstinclass mdm antihormonal therapeutics like abiraterone disorders pain location body increasingly often antagonistp activation investigational medicine potentially extend duration benefit ipatasertib molecular structure protein markers genetic inhibits tumour cell growth induces tumour also studied combination chemotherapy multiple sclerosis mutations signalling pathways scientists cell death phase iib study idasanutlin showed patients triple negative breast cancer positive results two phase iii studies verifying root genetic causes finding new ways consistent durable complete remissions rr aml opera opera ii ocrelizumab relapsing conquer difficult treat lifethreatening disease hemophilia ms one phase iii study oratorio primary high morbidity unmet medical need idasanutlin hemophilia rare genetic disorder occurs progressive ms presented relapsing ms leukemia lymphoma showed orr single agent orr essential bloodclotting protein called factor viii ocrelizumab significantly reduced annualised positive data phase ii study combination chemotherapie arac either present sufficient amounts defective relapse rate primary endpoint studies venetoclax investigational small molecule phase iib study fda granted breakthrough therapy nearly compared interferon medicine developed partnership abbvie designation emicizumab ace rg twoyear period primary progressive ms showed clinically meaningful reduction patients rr aml need new therapies bispecific antibody treatment factor viii oratorio study met primary endpoint showing number cancer cells overall response rate orr increase survival since inhibitors people severe hemophilia treatment ocrelizumab significantly reduced people previously treated relapsed significant progress regard last four years older development inhibitors risk progression clinical disability sustained refractory chronic lymphocytic leukemia cll decades addition phase iii trial idasanutlin antibodies developed bodys immune system least weeks compared placebo p deletion firstinclass molecule also studied phase ibii trials combination attack destroy replaced factor viii binds bclprotein helps restore natural venetoclax aml combination serious complication hemophilia treatment alzheimers disease process causes cancer cells selfdestruct gazyvagazyvaro nonhodgkin lymphoma regardless disease severity making difficult research focuses several pathways believed study patients previously treated cll addition investigating rg bispecific impossible achieve level factor viii sufficient play important roles disease including genetic mutation known p deletion antibody targets cdcd rg designed control bleeding traditional replacement amyloid tau clinical research findings presented mutation seen approximately bind target patients leukemia lymphoma therapies based encouraging data phase confirm hypothesis amyloid plays cll patients typically poor results cells cd whilst time binding iii study showed promising efficacy important role development progression existing therapies target cells cd redirecting cells weekly subcutaneous administration emicizumab ad addition early research indicates tau may attack cancer cells antibody different first pivotal studies started enrolment late implicated disease multiple pathways venetoclax studied phase ii iii trials mechanism action rituximab currently trial evaluate emicizumab people potential pathologies contribute develop cll phase ii studies several used treat blood cancers preclinical testing hemophilia inhibitors factor viii ment progression disease research blood cancers abbvie submitted nda suggests could circumvent rituximab resistance years older preparing initiate portfolio positioned well contribute significant fda breakthrough therapy designation additional trials including phase iii trial advances disease area continue generate ema submissions regulatory authorities emicizumab people hemophilia without data early late development stages around world planned see astermark j overview inhibitors seminars hematology roche innovation innovation roche two investigational compounds latestage amyotrophic lateral sclerosis sma affects motor neurons muscles used smnsplicing modifier rg clinical testing development crenezumab monoclonal antibody also conducting research amyotrophic activities crawling walking head neck clinical trial investigating safety tolerability designed target forms amyloid lateral sclerosis also known lou gehrigs disease control swallowing one common pharmacokinetics pharmacodynamics rg moved phase iii clinical development disorder involves death neurons rare diseases one born sma healthy individuals started january prodromaltomild ad monoclonal antibody especially motor neurons people progressive gantenerumab designed decrease levels neurodegenerative disease suffer stiff muscles olesoxime rg investigational medicine huntingtons disease aggregated amyloid recruitment muscle twitching gradually worsening weakness evaluated potential ability preserve rare genetic neurological disease hd causes stopped phase iii study gantenerumab people due muscle wasting results difficulty healthy spinal motor nerve cells results two peopleto experience deterioration mental mild dementia due ad marguerite road speaking swallowing eventually breathing year phase iiiii clinical trial involving people abilities motor control presently analysis data phase iiiii scarlet road type nonambulatory type sma indicate diseasemodifying treatments hd study provided evidence people early ad neurodevelopmental disorders olesoxime stabilised neuromuscular function collaborating ionis pharmaceuticals develop might benefit higher dose gantenerumab continue commitment finding new treat well reduced medical complications associated rnatargeting medicines treatment hd participants scarlet road marguerite ment options people neurodevelopmental disease two years compared placebo mid first patient entered phase iiia road studies offered treatment disorders including autism spectrum disorder olesoxime cholesterollike compound binds clinical study evaluate ionishttrx first higher dose gantenerumab assess tolerability syndrome phase ii trial underway proteins found mitochondria cells source therapy enter clinical development designed safety upon evaluation higher dose data test safety tolerability va receptor cellular energy production powerhouse reduce production forms huntingtin discussions health authorities antagonist rg people autism spectrum cell olesoxime designed reduce release htt protein including mutant huntingtin decide next steps clinical development disorder compound may improve core cell death factors mitochondria promotes protein responsible hd gantenerumab social communication interaction deficits survival spinal motor nerve cells olesoxime people disorder granted orphan medicinal product designation immunology inflammation parkinsons disease treatment sma european medicines different types rg monoclonal antibody targeting syndrome ongoing phase ii agency orphan drug designation fda autoimmune diseases many chronic synuclein protein may misfold study investigating rg adolescents adults debilitating even lifethreatening involved pathogenesis pd development years age started another collaboration ptc therapeutics currently available therapies unspecific generally collaboration prothena rg currently phase ii trial studying investigational compound sma foundation developing smnsplicing targeting immunosuppression addressing studied phase trial involving people children six years age preclinical data modifiers treatment sma phase ib disease cause expanded immunology pd inhouse developed smartphone app shown selectively modulating gabaa moonfish trial investigating safety rg inflammation research early development continuously measures symptom fluctuation receptors brain may possible stimulate people sma placed clinical hold april efforts recognition high unmet need people pd potentially first time learning memory pathways leading improve decision suspend dosing moonfish recent scientific advances lead better approach used measure disease ments cognition well functioning adaptive taken roche precautionary measure standing molecular mechanisms underlying symptom severity medicine development behaviour people syndrome observing unexpected finding animal study diseases scientists focused pathways programme pd remote patient monitoring evaluating longterm safety rg continue underlying adaptive immunity innate immunity system works combination patient spinal muscular atrophy thoroughly assess safety finding ongoing well tissue inflammation fibrosis input passive tracking app used rare debilitating genetic neuromuscular animal studies advanced second backup ongoing trial continuous measurement disorder sma commonly diagnosed daily symptom fluctuation ultimately children leading hereditary cause infant hoped app used future clinical mortality sma caused mutation deletion development enable objective measures smn gene characterised insufficient patient response treatment complement levels smn protein leads progressive loss physicianled assessments motor neurons muscle weakness atrophy roche innovation innovation roche increased risk future severe exacerbations decline lung function severe asthma lead unacceptable daily symptoms hospitalisations one internal programmes cathepsin diseasemodifying therapy ga lampalizumab cats inhibitor rg believed phase iii studies currently ongoing reduce amount specific molecules available severe asthma impacts quality life patient caregiver also increases medical burden society antigen presentation therefore limiting immune additionally pioneering development response rg could potentially applied highly innovative bispecific monoclonal antibody treatment multiple autoimmune diseases cats rg targets vegfa angiopoietin involved central pathways adaptive immunity ang two angiogenic growth factors meaning severe asthma current medications another programme rg gdc novel spur blood vessel growth rg phase ii infectious diseases brutons tyrosine kinase btk inhibitor helps clinical study neovascular amd rg rise bacterial resistance become threat break severe asthma cycle block b cell proliferation resulting excessive bispecific antibody developed rocheinvented global health line strong legacy immune response seen autoimmune disorders crossmab technology tightly bind vegfa one antibiotics leveraging significant knowhow gdc binds btk novel way arm ang arm randomised active address st century problem early studies believed increase effectiveness offers comparatorcontrolled phase ii study currently underway novel antibody targets potential one compound phase ii rg tlr promise patients difficulttotreat investigating safety efficacy rg cause reinfection staphylococcus aureus agonist two compounds phase rg autoimmune diseases patients choroidal neovascularisation secondary leveraging breakthrough cancer technology rg development rg led amd using leadingedge trojanhorse type platform partner inovio several molecules hbv parallel discovery activities strive sneaks drug bacteria platform may portfolio developed rd centre alliances area key academic respiratory diseases potential resistant infections also shanghai china recognition heavy burden biotech partners october acquired rg lebrikizumab targets protein found people partnership meiji seika pharma fedora hbv puts china sdp adheron therapeutics rg moderate severe uncontrolled asthma developing nextgeneration lactamase monoclonal antibody targeting cadherin phase iii development data expected inhibitor rg also advancing candidates treating patients believed disrupt tissue cell interactions drive thorax published phase iib study results hepatitis c virus hcv infected inflammation nonimmunosuppressive manner showed lebrikizumabtreated patients antivirals million people danoprevir second december partnered proximagen high level periostin reduction asthma past decade pegasys important generation hcv protease inhibitor developed develop novel oral small molecule inhibitor attacks compared patients medicine treating patients hepatitis b patients asian origin rd centre vascular adhesion protein vap celladhesion low level periostin companion test identify virus hbv roche continues explore ways treat china collaboration ascletis phase ii molecule may effective treatment high periostin levels developed inhouse potentially lifethreatening liver infection study danoprevir combination pegylated inflammatory diseases support physicians personalising asthma therapy affects estimated million people rich interferon plus ribavirin showed sustained viral hbv programme advanced three compounds response patients certain genotypes ophthalmology lebrikizumab also phase ii trials treatment clinical development believed interfere subtypes hcv research focuses neovascular agerelated idiopathic pulmonary fibrosis ipf moderateto hbv different way promote antiviral responses macular degeneration amd diabetic macular severe atopic dermatitis moderatetovery severe edema diabetic retinopathy glaucoma geographic chronic obstructive pulmonary disease copd atrophy ga glaucoma ga advanced form phase ii ipf study extended compare amd affects five million people globally combination esbriet plus lebrikizumab developed world currently therapies esbriet alone approved ga fda granted fast track designation lampalizumab treatment addition evaluating erivedge treatment wong wl et al global prevalence agerelated macular degeneration disease burden projection systematic review ga secondary amd lampalizumab anti currently approved advanced basal cell carcinoma metaanalysis lancet glob health hanania na et al lebrikizumab moderatetosevere asthma pooled data two factor fab selective inhibitor complement abcc gdc additional molecule randomised placebocontrolled studies thorax hepatitis b fact sheet messina jp et al global distribution mediated inflammation potentially first acquired esbriet intermune acquisition prevalence hepatitis c virus genotypes hepatology roche innovation innovation roche forwardlooking partnerships genome sequencing centre world sequence effectiveness difficulttotreat bacterial infections analyse tens thousands deidentified dna novel lactamase inhibitor rg clinical trials across therapeutic areas potential expanded spectrum multi mutual benefits collaboration drug resistant bacteria clinical development another exciting collaboration andme programme track enabled efficient analyse whole genome sequencing data trusted collaboration partners approximately individuals andme programme phase trial rg parkinsons disease community immediate studied treatment severe infections caused external innovation crucial strategy next milestone roches strategy using highquality family members find potential drug targets enterobacteriaceae spp bringing innovative treatments patients areas healthcare data advanced analytics improve disease currently cure unmet medical need currently manage development medicines decisions partnerships cancer immunotherapy partnerships worldwide partnered products patient care collaboration fmi infectious diseases roche initiated number clinical contribute third pharmaceuticals sales roche acquired majority stake april roche strong legacy antibiotics two collaboration studies external partners rd pipeline compounds externally leverage companies strengths advance antibiotic products developed roche listed combine lead cancer immunotherapy drug sourced science businesssavvy partnering progress discovery development essential medicines list current atezolizumab broad number tumour teams work closely internal rd gauge needs personalised treatments cancer patients research strategy infectious diseases focuses types see table gaps standardise data collectionanalysis clinical areas high unmet medical need incidence trials settings clinical practice drugresistant infections creating urgent innovation procurement time closely follow emerging demand new therapeutic options early pharmaceuticals division built companies around globe academic advances collaboration also includes development roche meiji seika pharma fedora joined forces innovation centre excellence collaborate closely alliance opportunities screening companion diagnostics based nextgeneration tackle increasing bacterial resistance antibiotics key suppliers innovation innovation thousands potential partners year selecting sequencing enables comprehensive genetic profil licensed investigational nextgeneration business cases approved end versus truly help us raise bar drug ing basis limited amounts cancer tissue lactamase inhibitor rg compound target business cases discovery development strategic agreement makes fmi organisationally targets lactamase enzymes combination launched since initiation approach part global roche pharmaceuticals division new existing lactam antibiotics enhance roche partnering signed new agreements fmi retains operational independence foster including four acquisitions four product transactions innovative energy entrepreneurial spirit research technology collaborations eight product outlicensing agreements among first ten pharma biotech companies came forward create gene genentech partnering genentechs research consortium genomics england announced new contracts group signed new agreements including collaboration part genomes project clinical trial collaborations cancer immunotherapy including atezolizumab three product transactions research accelerate development new diagnostics collaborations treatments patients disease investigational medicine external partner nonsmall cell lung cancer mutantselective egfr inhibitor rocilietinib clovis oncology us molecular information dna analysis genentech partnering signed two molecular triplenegative breast cancer colorectal immunotherapy talimogene laherparepvec amgen us several key deals capitalised emerging information collaborations help identify cancer liver metastases tvec field molecular information rapidly evolving new drug targets biomarkers well provide softtissue sarcoma cmb immune design us role targeted medicines diagnostic solutions insights likely get disease renal cell carcinoma cdtargeting antibody varlilumab celldex therapeutic us collaborations established foundation progresses genentech using human triplenegative breast cancer entinostat syndax pharmaceuticals us medicine fmi flatiron health mark longevity established largest human advanced solid tumours cpi corvus pharmaceuticals us roche innovation innovation roche personal perspective exciting work patient reports juncture match tumour profile targeted therapy ongoing trial genomics patient able continue active lifestyle medicine outcomes positive deeply gratifying know work immediate impact cancer patients treatment involved developing decision support kim pelak phd data scientist tools help patients benefit methodologies well vast molecular foundation medicine information knowledge base example worked reporting tool empower pathologists create reports customising unlocking cancers content patients majority patient reports potentially actionablethey give options treating physician genomic tests used roche clinical genetic code hope patient already trials breakthrough cancer immunotherapy sequenced tumours individuals molecular information also play key role identifying novel drug targets incredibly revolution genomics began fascinate historically oncologists primarily interested exciting time work juncture genomics middle school scientists spoke tissue cancer originated medicine grateful part enormous potential personalised example breast cancer treated differently healthcarebut still largely hypothetical colorectal esophageal cancer today know three cancers others driven today foundation medicine cutting molecular malfunctions potentially treated edge translating persons unique tumour profile targeted therapy thats foundation personalised therapeutic options treating medicine tests genomic variants across patients cancer basis strategic genome regardless type cancer partnership roche sometimes get chance see impact first sequence genome patients cancer work remember presentation one female using blood tumour tissue search genetic patient marathon runner prime life variants play role various types cancer suddenly diagnosed stage iv lung cancer curators sift huge databases match bone metastases colleagues sequenced findings targeted therapies including tumour found genetic variation data contribute rd molecularly match patients studied thousands ongoing clinical trials corresponding targeted therapy treatment appropriate trials therapies roche innovation innovation roche basket trials umbrella trials brain ovarian skin lung bowel example glioblastoma brain tumour innovative approaches new medicines new insights new procedures mutation causing different manifestations different medicines hit target using realworld data inform rd decisions validated standardised information helps baskets umbrellas clinical trial designs industrys longheld stepbystep development clinical trials patient registries hospitals researchers generate hypotheses improve new medicines combinations medicines process even traditional clinical trials healthcare providers insurance companies patient outcomes must fully tested made broadly abandoning linear timeconstrained protocols even online health sites smartphone apps available however era targeted therapies favour adaptive study designs build explosion healthcare information molecular data partnershipslike fmi ushering new ways perform studies ability alter aspects ongoing trial based recent years add genomic data generate sequence tumours dna cancer patients decadesold approach using phase ii iii patient responses new scientific understanding internally produced plethora andme sequence dna patients clinical trials giving way cuttingedge study biotech companies cheaply sequence parkinsons diseaseare supporting research designs realistically effectively allow parallel new clinical endpoints human genome short time relatively low cost focus helping us understand disease us evaluate promising compounds patients introduced assess impact investigational used appropriately healthrelated realworld fundamental cellular level develop best targeted medicines example pathological complete data rwd powerful resource providing therapies combinations therapies patients response medication given prior surgery invaluable insight medicines diseases highquality data critical informing research among pioneering studies underway pathologist confirms vital cancer cells impacts treatment time helping us design evaluate innovative firstofitskind basket study zelboraf found tissue sample taken surgery clinical trials approach puts metastatic melanoma braf status complete response confirmed however rwd vast complex varies mutationdriven tumours including brain lung colon approach already shown bring new treat dramatically quality reliability beyond clinic todays healthcare landscape ovarian single studyor basketand allows ment strategies patients much faster took captured managed analysed truly support demands holistic realworld information across us simultaneously evaluate whether zelboraf eight years herceptin get approved research ultimately improve patient care lifecycle products increasingly reimbursement effective treating different cancers traditionally presurgical neoadjuvant treatment comparable nutshell driving science one first decisions worldwide based whether new would require separate trials tumour perjeta approval took year half healthcare companies integrate rwd meaning medicines bring added benefit standard type zelboraf currently approved metastatic ful way drug development care patients daily lives regional melanoma caused braf mutation going beyond strict medical focus looking realworld data science rwds group created cultural differences affect treatment impact whole patient one firstever trials grow strongly next year rwds different elderly rwds group helping also involved ambitious multipartner examine personal preference cancer therapy biostatisticians become vital collaborators address data gaps well questions data public trial testing several drugs ongoing study comparing whether patients rd teams cull extract deliver relevant standardisation compatibility privacy umbrella tumour type glioblastoma herpositive early breast cancer would rather common technology frontiers leveraging patients treated different medicines herceptin administered subcutaneously intravenously expertise pharmaceuticals diagnostics including five marketed pipeline drugs strong relationships key industry based genetic mutation prominent whilst complex matter design new wave molecular data support research partners want take best advantage ocean tumour personalised approach innovative trials committed breaking informational opportunity swirling around real increases probability treatment success ground driving data generation accelerating help us understand diseases world data still young discipline believe provide invaluable data targeted drug development right therapies rapidly become crucial part achieving optimal medicines best candidates specific delivered right patients cellular level patient benefit mutations approaches upend roche innovation innovation roche innovation roche diagnostics minute subcutaneous tissue people sequencing ngs workflow top talent diabetes check data needed using continue invest leading technology develop wirelessly connected receiver current glucose products ultimately become integrated improving efficiency patient care value trend arrow glucose curve seamless endtoend sequencing solution diary pipeline technologies address every point sequencing workflow include sample preparation technology minimises numbers technologies singlemolecule sequencers data fingerpricks needed compared current standard analytics management tools testing drugresistant organisms utilising new reagents experts across approaches also provides extensive amount acquisition geneweave provides us roche diagnostics pharmaceuticals division data trend information particular importance recent acquisition kapa bioystems strengthens smarticles technology innovative new class working developing foundational multiplex programmable alarms person portfolio area sample preparation molecular diagnostics quickly identifies multidrug technologies translated new multiplex diabetes gets alerted glucose values rise fall foundation kapas technology custom enzyme resistant organisms mdros assesses antibiotic product opportunities strategy develop quickly essential people evolution technology allows generation susceptibility directly clinical samples without modular technologies accommodate wide able feel becoming hypoglycemic enormous libraries enzyme variants need traditional enrichment culture sample range biomarker expression detect biomarkers suffer socalled hypoglycemia unawareness ideal forms enzyme rapidly selected preparation processes first system development located cellular compartment eg especially dangerous nights expediting product development timelines vivodx fully automated randomaccess system nucleus whilst providing results timely affects significant number people diabetes investments including signature diagnostics designed rapidly meet needs laboratories manner single specimen digital pathology insulin therapy lumora heat elution technology complement addressing mdro detection antibiotic therapy integral part process imaging algorithm growing ngs portfolio reinforce long guidance technology evaluated development become critical rapid accurate first clinical studies innovative sensor term vision provide customers around world multiple sites across us interpretation complex staining patterns able demonstrate insertion wearing comprehensive genetic testing solution sensors overall well tolerated addition advancing multiplex technologies currently developing model immune panel results promising regarding high level turning data information era cancer immunotherapy view detecting expression cd cd cd cd sensor accuracy precision especially actively exploring opportunities increasing need test several biomarkers foxp markers related panels include hypoglycemic range diagnostics business area big data inform clinical decisions becoming critical detection pdl work streams encompass include use aggregated diagnostics information detect multiple biomarkers single slide darkfield plex brightfield plex assay nextgeneration sequencing improve quality patient care make preserving tissue context especially tissue formats use unmodified modified primary acquisitions partnerships initiated research development efficient also limited whilst conventional staining anatomical antibodies well amplified nonamplified past two years positioning us develop best use big data optimising business pathology typically limited one two biomarkers detection schemes progress promising inclass technology across nextgeneration laboratory developed series proprietary chromogenic providing customers bestinclass multi stains brightfield microscopy series plexing solution effective disease management fluorescent stains darkfield microscopy extend multiplexing capability addition increasing continuous management diabetes number simultaneously detected biomarkers newly developed continuous glucose monitoring reagents permit highly sensitive detection cgm system designed provide ongoing glucose available research use use diagnostic procedures roche diabetes care summary clinical investigation report study colocalised bio markers critical identifying measurements comprises glucose sensor atos freckmann g et al performance evaluation three continous glucose j diabetes sci technol zschornack e tumour heterogeneity characterising immune remains body seven days controller et al evaluation performance novel system continuous glucose monitoring j diabetes sci technol cell infiltrates receiver system measures glucose levels every wwwrochecomrndlocations wwwrochecomresearchtechnologies wwwrochecompipeline roche access healthcare access healthcare roche acce healthcare believe urgent deliver medical solutions right even develop innovations future thats committed working partners local level overcome barriers improve access tests medicines patients patient group delegates countries attended largest patient organisation meeting roche access healthcare access healthcare roche ur aim every person needs medicines diagnostic tests able access benefit significant breakthroughs diagnosing treating tailored plans address implemented serious diseases well improvements delivery several successful partnerships initiatives healthcare steadily improved health outcomes four key areas focus increasing awareness increased life expectancy recent decades strengthening infrastructure improving affordability however universal access medical innovation delivering innovation quality healthcare remains global challenge multistakeholder approach challenge complex multifaceted healthcare innovative products deliver value resources demands resources vary therapeutic well economic benefits example widely country country even within many products make healthcare delivery countries regions sophisticated new efficient improving mode admin medicines diagnostic tests readily available istration reducing time patients spend whilst others healthcare infrastructure hospital addition advances science led limited basic medical care still luxury personalised healthcare accompanying diagnostic test used identify patients likely believe critical uncover root causes respond specific medicine helps limiting access local level able optimise benefit patients ensure implement solutions make meaningful efficient use healthcare resources differences rolled access planning framework resulting improved insights specific requires playerspublic authorities non regional national challenges local level governmental stakeholders patient organisations local communities healthcare industry others work closely together whilst governments established partnerships primary responsibility establishing maintaining healthcare systems healthcare four reinsurers local insurance industry plays important role improving health global healthcare company roche shares companies improve cancer care responsibility tackle challenges improving health outcomes millions people across china roche access healthcare access healthcare roche healthcare professionals patients healthcare companies quality healthcare shared taking global challenge responsibility improving access country country regulators policymakers rise chronic diseases combined ageing sustainable solutions tailored locally population growing unemployment economic onesizefitsall solution single pressures aggravate inequalities access stakeholder tackle access challenges alone payers insurers healthcare leading poor outcomes therefore work many partners continuously regions world sustainably reduce barriers prevent limit people benefiting products delivery quality healthcare complex involves number stakeholders working partners local level address challenges help take impact cancer south east asia barriers may include lack disease awareness establish sustainable solutions example cancer among biggest causes screening diagnosis fundamental infrastructure morbidity worldwide causing million deaths including adequately trained healthcare professionals alone next two decades global availability treatments adequate care cancer mortality predicted occur low factors geographical political financial middleincome countries half deaths cultural barriers make effecting change occurring south east asia incredibly challenging country along patients journey receiving optimal strengthening national cancer plans treatment map critical stakeholders shape one effective way address burden cancer according action asean costs approach tailored individual healthcare strategies tactics overcome hurdles national prioritisation integrated local oncology study region needs country rather single topdown planning example poland cancer people experience death financial catastrophe approach provide comprehensive solutions ensure sustainability approach plans treatment outcomes among poorest europe within year cancer diagnosis urgent action increase awareness diseases healthcare options directly connected business linked worked several partners including polish needed protect populations financial strengthen healthcare infrastructure partnership commercial strategy local managements society oncology demonstrate need burden disease reduce impact loss local stakeholders improve availability annual goals also focused building improve cancer care white book polish economic productivity affordability products local functional expertise strengthen engagement oncology report highlighted gaps treatment stakeholders dynamic healthcare environments access medicines triggering highlevel debates aim every person needs products saw great engagement commitment ultimately ensure successful implementation many stakeholders developing sustainable able access benefit creativity shape access plans potential access plans improvement strategy resulted ministry happen several conditions need place make diagnostics medicines available many healthapproved publication national including disease awareness adequate healthcare patients around world following global comprehensive cancer strategy represents infrastructure sufficient medical coverage rollout workshops developed major step forward cancer care country committed working stakeholders countryspecific access plans plans improve outcomes across access spectrum analyse various hurdles encountered wwwrochecomaccesstohealthcare cancer factsheet iarc globocan estimated cancer incidence mortality prevalence worldwide kimman et al asean costs oncology published george institute global health support unrestricted educational grant roche asiapacific regional office uicc national cancer control planning non governmental organisations eurocare european journal cancer roche access healthcare access healthcare roche africa strategy initial implementation nigeria ghana kenya cte divoire angola ethiopia gabon shifting access paradigm africa ongoing outreach uganda senegal cameroon mauritius tanzania madagascar rwanda congo rdc congo rc mozambique tom principe equatorial guinea cape verde establishing longterm solutions africa strategy focusing countries aim increase access innovative treatments patients whilst creating longterm sustainable business environment african continent developing quickly initial analysis decided focus gdp expected increase significant countries strides made improving health outcomes many countries however major challenges remain commenced strategy seven particularly subsaharan africa countries nigeria ghana kenya cte divoire roche covering remainder programme diagnostic test provides dried blood spot testinga angola ethiopia gabon implementing aims treat additional patients viral simple innovative method collecting transporting poor outcomes persist subsaharan africa wide selection activities collaboration local hepatitis women breast cancer storing patient samples resourcelimited multitude reasons including low disease awareness partners including healthcare system strengthening five years settings hiv global access programme expands late presentation patients disease limited local data generation advocacy healthcare commitment providing viral load early quantity poor quality healthcare institutions prioritisation building infrastructure disease increasing access hiv diagnostics infant diagnostics affordable price offerings lack medical specialists uncertain supply chain management support awareness advocacy africa strategy builds upon successes countries highest disease burden primarily quality low government priority little local campaigns treatment guidelines education roche access programmes efforts across africa prevalence data limited funding market access solutions healthcare improve hiv testing worldwide leading professional training private health insurance provider hiv viral load testing roche long increasing access viral load early infant million people hepatitis b subsaharan local companies pricevolume agreements standing commitment expanding access hiv hiv testing helping strengthen diagnostic africa whilst women diagnosed governments diagnostics around world capacity improve quality hiv treatment breast cancer estimated women services helps support global unaids die cervical cancer africa every year breakthrough agreement cte divoire people living risk contracting goal ensuring people receiving committed improving outcomes disease new cases per year breast disease access adequate prevention antiretroviral therapy achieve viral suppression areas across region cancer leading cancer women cte treatment care improving laboratory capacity divoire cases disease detected critical order ensure people living hiv programme run partnership taking holistic approach cancer become advanced meanwhile access diagnostic tests monitoring joint united nations programme hivaids africa strategy one part overall strategy hepatitis b first cause liver cancer treatment need clinton health access initiative unitaid us analyse access barriers countrybycountry country prevalence presidents emergency plan aids relief basis develop tailored solutions local partners january launched hiv global access global fund fight aids tuberculosis malaria aim increase access innovative treatments roche commenced new programme programme offering sustainable solutions hiv patients subsaharan africa whilst creating partnership cte divoire ministry health viral load tests eligible low middleincome since seven million infants longterm sustainable business environment improve access tests innovative medicines countries programme covers countries conducted indepth analysis countries africa comprehensive approach roche supporting close global population people hivtested roche using multitude factors disease incidence government raise disease awareness train infected hiv beyond programme also urban population growth middleclass emergence healthcare professionals build diagnostic covers early infant hiv testing timely hiv infant diagnostics global access programme healthcare spend government focus healthcare capabilities regarding treatment patients pay diagnosis greatly improves disease management minimal portion cost government outcomes hivinfected infants roches early infant afdb oecd undp african economic outlook cervical cancer fact sheet islami f et al tumor size stage breast cancer cte divoire republic congo results populationbased cancer registries breast yoman n et al occult hbv infection untreated hivinfected adults cte divoire antivir ther roche access healthcare access healthcare roche personal perspective think part strategy increase local expertise roche providing full scholarships five medical oncologists additional ten years diagnostics divisions example installing tissue diagnostics machine public cancer treatment centre additionally provide training pathologists technicians life means also committed assisting ministry health gathering accurate data cancer cancer registry development partnering support training provide infrastructure including beatrice nyawira md laptops software good data provide clearer picture actual disease burden inform policy medical manager roche kenya resource allocation addition partnering government public healthcare programme increase access reducing access innovative breast cancer medicines go low eight months developed countries ten years think everything coming together cancer finally barriers kenya additional ten years life means woman getting voice media advocacy could raise children start new career realise government open willing act dreams difficult put value commitment could come better time became medical doctor felt deep words truly believe make huge difference need help people seeing patients every day improving cancer treatment kenya six years realised ability roche kenya partnering government impact overall healthcare environment break access barriers oncology treatment limited thats joined roche goes well beyond price drugs awareness diagnosis increasing capacity today colleagues working expertise healthcare professionals treatment fundamentally change treatment paradigm access looking whole continuum oncology whilst infectious diseases hiv malaria tuberculosis remain priority part programme offer full africa cancer received attention scholarships additional five medical oncologists deserves kenya sponsor programme train oncology nurses local medical school eldoret also particularly breast cancer incidence rates conduct preceptorships local international approach western countriesbut experts improve mastectomy diagnostic mortality rate much higher life expectancy techniques cancer diagnosis leveraging forging new partnerships change paradigm kenya breast cancer patients diagnosis collaboration pharmaceuticals diagnosis treatment breast cancer roche access healthcare access healthcare roche personalised reimbursement model framework working within healthcare systems multiple indication pricing combination pricing pay response allows medicine priced according ensures benefits combination therapy bases level reimbursement patients increasing access tests medicines benefit delivers different indications reflected whilst taking consideration limits response medicine specified time period healthcare budgets approach allows price differentiation reflect benefit treatment delivers patients bringing product market work closely determine appropriate payout treatment governments insurers healthcare launch affordable cancer insurance policies providers determine value enables us cover best available treatment access demonstrate value product patients hospitals doctors cancer education families healthcare professionals payers society support approximately million policies palliative care partnership likely trigger france whether based indication line treatment general order gain appropriate reimbursement since sold china similar arrangements coming months duration treatment treatment combinations adds choice national health however recognise despite improvements october roche signed contract personalised reimbursement models authorities wider range potential pricing healthcare infrastructure funding innovative large insurance company shenzhena city whilst reimbursement today based solutions discuss roche ultimately medicines diagnostics remain beyond reach population million peopleto ensure avastin undifferentiated price per item personalised benefit patients many patients need therefore exploring reimbursement list metastatic colorectal reimbursement models prms allow medicines new pricing access models tailored cancer shenzhen become first city priced according benefit deliver wide spectrum innovative pricing models dynamics healthcare system rather china four roches targeted therapies developed several innovative pricing uniform pricing structure innovative approved country mabtherarituxan prm framework includes multiple indication models tailored needs patients different approaches include personalised reimbursement avastin herceptin tarceva reimbursed pricing allowing medicines priced according healthcare systems example international models differential pricing patient assistance roche aiming significantly increase patient benefit deliver different indications differential pricing programmes help reduce programmes private insurance coverage access rate china herceptin mabthera combination pricing benefit combined prices governments facilitate reimbursement rituxan next two years therapy reflected whilst taking account budget medicines prescribed public healthcare governments emerging developed regions constraints pay response reimbursement systems prices based adjusted gdp per finding increasingly difficult fund access new access initiatives europe based patients response medicine capita country question roche believes innovative treatments cancer diseases meanwhile portugal due budget constraints specified time period price differentiation countries public budgets alone roche actively supports across public sector access innovative improve patient access innovative medicines innovative approaches improve treatment coverage treatments via national system become prms introduced across europe markets significant access problems including private insurance complement increasingly difficult roche investigated publicprivate markets already taking part example france public funding healthcare partnerships started work two initiated pilot phase hospitals developing regions sell second brands important health insurance companies country validate feasibility prm approach breast products subject quality expanding private insurance coverage china expanding insurance companies coverage help cancer treatment scaled initiative control original product different china small portion population close funding gap significantly hospitals names sometimes slightly different forms health insurance policy covers costs cancer france taking part vials rather syringes additionally treatment roche teamed four reinsurers october health insurance market leader patient assistance programmes help provide access local insurance companies including three introduced firstever private health scheme different pricing models based value medicines underinsured largest help develop policies cover cancer portugal covering entire spectrum patients considered countries uninsured patients cancer treatment care enabled companies care monitoring disease treatment roche access healthcare access healthcare roche partnering key stakeholders elevating patient voice organised harnessing power women drive positive change oncology beyond panel discussion world cancer leaders summit finding equitable sustainable solutions focusing societal value innovation global barriers healthcare achieved policy level helping facilitate persistent commitment action conversation measure value new improve cancer care access outcomes people affected multiple sclerosis developed multiple stakeholders succeed must jointly innovative treatments climate cost constraints members society support platform multidisciplinary group experts supported develop innovative sustainable ways bring effective limited healthcare budgets european developed report women change agents educational grant roche presented affordable healthcare people improve health forum gastein leading health policy confer oncology explore reducing european committee treatment research health outcomes ence held interactive session collaboration burden cancer women add value patients multiple sclerosis recommends policy several european health associations healthcare systems society changes ensure people disease un underlined importance promoting good topic session scoping value innovation able receive effective treatment early health globally sustainable development measuring unmeasurable attracted wide range increasing collaboration patient groups impact lifelong course disease goals roche supports see stakeholders levels health systems take patient engagement seriously roche recommendations made report details key part achieving goal ensuring endeavour support patient organisations endorsed number professional associations universal health coverage including access clear call value analysis objectives possible today interactions advocacy groups healthcare services medicines vaccines people take account price innovation patient groups multifaceted range living developed developing regions clinical outcomes also consider broader funding organisations building capacity also supported patientdriven idiopathic impact families communities employment organising meetings supporting advocacy see pulmonary fibrosis ipf charter calls roche joined stakeholders economy details decisionmakers take action improving ipf supporting drive universal health coverage patients quality life well support welcomed trend toward evidence value reducing burden cancer society international experience exchange patient development longterm treatments work based decisionmaking resource allocation also key theme world cancer leaders organisation ieepo roches largest global patient towards cure lowresources settings crucial target limited summit joined leaders united organisation meeting held munich health budgets toward interventions services nations agencies national ministries health patient focused vital role patient organisations also established preapproval access provide benefit value organisations academia private industry record total delegates countries medical ethics group within office greatest number people organised harnessing power women attended ieepo agreed potential chief medical officer focuses ethical drive positive change oncology beyond panel role patients play research clinical trial design patientcentred approaches clinical research respect health technology assessment hta discussion investigated direct indirect recruitment hta aspects drug preapproval access investigational medicines become key tool help countries allocate burdens cancer imposes specifically women development access could increase going forward aim increase valuable health resources efficiently equitably roles family members caregivers patients significantly exchange hope incorporate patient based evidence supporting affiliates perspective defining potential value new understanding approach best panellists explored ways harness growing international report brain health time matters innovations bring peoples lives ensure optimal access innovative treatments political power social scientific prominence multiple sclerosis aimed improving outcomes local level women ensure policy prioritisation action wwwrochecomstakeholderengagement european cancer league european health management association international association mutal benefits societies european patients forum wwwrochecompatientgroups giovannoni g et al brain health time matters multiple sclerosis published oxford pharmagenesis ltd funding educational grant roche ipf patient advocacy groups european ipf patient charter initiaitve supported roche roche responsible business responsible business roche pon sible bu sine compliance license operate serves foundation build maintain trust stakeholders supplie r audit conducted global local level roche responsible business responsible business roche w e committed improving lives nearly years led spirit running business socially responsible way united nations general assembly issues like yearly sustainability forum unanimously adopted sustainable development internal stakeholders external goals sdgs end poverty protect planet experts discuss innovations supply chain ensure prosperity part foster access healthcare improve sustainability sustainable development agenda agreement reporting affiliate level enhance marks important milestone next phase employee engagement example roche sites like sustainable development engagement mannheim penzberg basel introduced wide range stakeholders platforms employees contribute ideas improve working environment processes committed supporting number half employees mannheim penzberg sdgs line business strategy particular worked continuous improvement sdg aims ensuring healthy lives activities additionally employees submitted promoting wellbeing beyond communicable ideas leading savings eur million diseases tuberculosis malaria non mainly resulted waste reduction pharma communicable diseases including cancer mental diagnostics manufacturing well general disorders also universally recognised areas optimisation manufacturing logistics high unmet medical need forefront developing effective therapies diagnostic tools compliance license operate diagnose treat monitor cancer neurological take responsibilities seriously order disorders see details one objective meet high standards business ethics integrity sdg achieve universal health coverage instrumental sustainable success prerequisite achieving better access safe hence ability make lasting impact effective highquality medicines diagnostic public health integrity roche means things tests developing innovative approaches right start strongly believe people collaboration international local players important success factor compliant strive break access barriers many behaviour starts line managers right patients around world supporting universal mindset responsible careful healthcare coverage goal see details selection instruction monitoring teams compliance goes beyond line management stakeholder engagement key pillar roches every employee accountable comprehensive sustainability management process behaviour approach forms foundation allows us identify prioritise material comprehensive compliance management system wwwrochecomstakeholderengagement roche responsible business responsible business roche group risk report annually fostering culture compliance suppliers service providers findings sustainability employment contracts terminated expectations employees expressed audits category grounds unethical behaviour agreements discussed executive management roche group code conduct designed business partners also terminated set standards business behaviours reason provide guidance employees ethics launched revised roche group code conduct labour managing opportunities risks assessing sustainability risks opportunities helped foster awareness health safety risk management policy sets approach established business sustainability risk integrity utmost importance within organ environment identifying managing reporting internal process allows us assess emerging risks isation addition new version elearning managementsystems external risks opportunities group risk developments annual basis integrate course support good records management practices management process embedded levels existing group risk management audits conducted ranges provided indicate percentage introduced records management one findings category roche helps suppliers follow organisation using consistent methodologies process year emerging sustainability risks component roches code conduct defines findings processes routinely perform risk assessments developments identified assessed create manage retain discard records group risk report covers material risks expert crossfunctional team new categories accordance laws regulations speaking right thing annually discussed corporate executive identified consider include countries operate training module primary goal create environment committee reviewed audit committee appropriate previous years emerging risks mandatory employees businesscritical mutual trust issues discussed open board directors developments contractors dialogue potential violations prevented employees encouraged speak group risk advisory team provides advisory digital evolution companies becoming roches suppliers service providers expected compliance concern using available speakup services sites affiliates project product teams dependent cuttingedge information adhere standards employees channels employees used roche group facilitates risk discussions support business technology digital data hence raising roche supplier code conduct included speakup line available languages many specialist areas digital media question data integrity data confidentiality contracts offer elearning programme countries employee raises compliance security compliance sustainability elearning cyber threats cloud security also considered help suppliers service providers increase concern good faith acts interest roche programmes classroom training workshops risk innovation constant evolution life sciences knowledge understanding roches expectations deserves acknowledgement roche tolerate roundtables crossdivisional risk forums technologies requires companies adapt industry standards retaliation employee raises place improve understanding risks help innovation strategy order constantly embrace compliance concern good faith employees manage appropriately scientific progress business opportunities also operate stringent process qualify corporate evolution global corporations exposed audit current new suppliers service providers chief compliance officer received continue strengthen business continuity growing complexity business environment conducted audits reports relating alleged violations code management bcm ensure sites including increasing number thirdparty global local suppliers service providers conduct via business ethics incident reporting affiliates respond effectively catastrophic events relationships partnerships main findings suppliers related quality health system vast majority reports related develop strategies tactics deliver minimum government society companies safety whilst findings service providers occurred personal integrity cases expense fraud conflict acceptable level key products services group include multiple stakeholders decision primarily quality social managerial areas interest abuse company assets harassment bcm policy guideline facilitates consistent making process including governments non helped suppliers follow findings discrimination remainder related violations aligned approach local implementation governmental organisations citizen groups company integrity good practice marketing demographic evolution companies challenged antitrust false records allegations preparing influenza pandemic covered rethink adapt operating model fit societal roche group code conduct unfounded still investigation group influenza pandemic policy based expectations needs eg flexible workplace founded allegations subject recent interim guidance sites available different languages careful investigation allegations founded required updated influenza pandemic adequate corrective measures sanctions taken plan place properly tested wwwrochecomcodeofconduct wwwrochecomrochesuppliercodeofconductpdf wwwrochecomsuppliers wwwrochecomriskmanagementandcompliance roche responsible business responsible business roche working governments improve public health increasing transparency actively engaging government officials committed transparent reporting industry bodies order contribute endeavour drive social environmental public debate development effective performance diligence financial public health laws regulations policies performance follow global key areas discussion engagement reporting initiative g guidelines disclose future brings new challenges opportunities based development disruptive information technologies core application level also report number eu data protection regulation vitro additional indicators diagnostics regulation access innovative medicines patient organisations important partners us biosimilars payment reform patient roche throughout interactions committed separated commercial medical also publish data voluntarily global level access healthcare ensuring collaborations reflect shared organisations pharmaceuticals part sustainability reporting values integrity maintenance independence diagnostics divisions differentiating clearly roche remains independent political affiliation respect mutual benefit support patient nonpromotional activities medical scientific contributions healthcare institutions however support number associations organisation always based written agreement intent promotional activities addition total amount chf million political institutions switzerland spent around clearly states purpose amount separation established pharma healthcare chf million includes payments financial support includes description compliance office effectively support line manage industry associations various chambers significant indirect nonfinancial benefits ment compliance responsibilities education healthcare professionals commerce financial assistance trade unions research donations political parties cantonal accordance industry guidelines make roche dedicated engaging productive education patients general public federal level donations political parties public details relationships patient transparent dialogue collaboration healthcare lowdoubledigit thousand swiss franc range organisations list updated annually professionals healthcare organisations disclosing clinical information benefiting society overall less total contributions published website committed satisfying legitimate requests roche committed sharing data clinical trials donations information results research taken significant steps recent years contributions patient organisations development activities transparent accurate enhance share clinical study information eligible employees us make personal total amount chf million timely way political contributions roches good publishing protocol study results information government committee ggc genentechs throughout new divisional guidance clinical trial registries political action committee genenpac research projects implemented regarding interactions healthcare disclosing appropriate clinical study voluntary political action committees workshops seminars meetings professionals organisations including grants documentation clinical study reports csrs ggc genenpac jointly contributed approximately educational grants sponsorships donations healthcarerelated peerreviewed publications presentations usd candidates candidate committees service contracted patient organisations entities training information sessions providing qualified researchers access disease awareness general education organised train employees across group patientlevel clinical trial data new guidance cases disclosures made safeguard transparent contributions patient privacy collaborate number healthcare professionals organisations groups involved advancing opportunities data committed full compliance laws sharing engagements include partnerships regulations industry codes requiring disclosure established clinicalstudydatarequestcom eg us sunshine act efpia disclosure code transcelerate wwwrochecomnonfinancialreporting wwwrochecompatientgroupslist wwwclinicaltrialsgov httpseudractemaeuropaeu wwwclinicalstudydatarequestcom roche responsible business responsible business roche personal perspective compliance asking making decision right thing need additional clarification help always call compliance resources regional policyits global level compliance policyits mindset asking making mindset decision whether right thing mindset part organisation since launching compliance champions initiative evolving compliance journey creating environment spend much less time evaluating potential compliance issues ameya telang finance director also see impact external stakeholders compliance officer roche philippines doctor asks whether spouse partner attend roche event example politely decline explain terms integrity standards integrity basis strengthens position reputable company govern interactions doctors hospital administrators patients many stakeholders believe strongly patients business roche job dont direct influence took job need discovering developing new drugs deepen understanding compliance healthcare contribute making business sustainable truly say grew roche father regulations internal guidelines done something matters worked company years evolving rapidly sometimes questions ambiguities always impressed roches values arise people needed information resources close hand today still believe firmly roches values work roche philippines finance director thats established compliance champions responsible meeting objectives compliance philippines since every function across officer job ensure sell products pharmaceuticals diagnostics diabetes care ethical manner rely science compliance champion contact person clinical data behind products convince decision much easier colleagues consult makers value catalyst change organisation pharmaceutical industry highly regulated employees longer looked compliance separate roche goes beyond regulations ensure function part daily work internal employees compliant high ethical standards expertise helped us illuminate grey areas become work compliance champions every function embed area healthcare compliance standards proactive addressing potential issues proactive thinking daily work roche responsible business responsible business roche putting patient safety first distribution channels combat reducing animal testing minimum counterfeiting market strengthen legislation like researchbased healthcare companies roche conducts animal tests required regulatory continuously improving safety standards council europe drafted convention authorities however test results constitutes first time binding international achieved using scientifically acceptable alternatives instrument criminal law field counterfeiting animal testing always use invest medical products similar crimes involving significantly development testing methods threats public health medicrime convention using computer simulation isolated cells grown ensuring patient safety effectiveness roche internal quality compliance audits convention came effect january petri dish switzerland support r products top priority collaborate regular basis ensuring compliance good research foundation funds development regulatory agencies monitor reports adverse events manufacturing practice standards approx initiated programme roche increase improvement methods based r strategy experienced patients communicate imately inspections conducted health security supply chain implementing replace reduce refine product safety activities authorities roche manufacturing sites focus number new technologies including overt proactive corrective preventive actions address covert anticounterfeiting features barcoding used animals internal products wellcharacterised benefitrisk nonconformities determining causes mass serialisation techniques tamperevident research number animals used contract profiles updated throughout life ensure sustainability operations packaging completion programme slated research organisations cros working roches product adverse events stored global data every roche product folding box case behalf increased approximately base reviewed qualified physician reported quality system instrumental maintaining pallet unique identification animals used mice rats major sites promptly appropriate regulatory authorities right operate overall successful health awarded continued full reaccreditation status required addition communicating openly authority inspections health authority interactions defining regulatory frameworks biosimilars association assessment accreditation regulators stakeholders require system also enables timely approval order ensure safety patients develop laboratory animal care international underscoring employees immediately report drug safety new products corresponding successful pre ment manufacture biosimilar monoclonal commitment ensuring animal welfare quality issue respective safety personnel approval inspections antibodies must subject rigourous clinical employees complete mandatory programme regulatory standards well postmarketing total number animals used research every year ensure full awareness adverse roches pharma technical operations unit pharmacovigilance protections roche cros decreased vs event reporting tasked ensuring availability roche medicines worldwide maintains quality plan roche supports development regulatory medicines leave manufacturing process foundational across operations quality frameworks introduction biosimilars must meet highquality standards roches manual highlights key actions continually improve actively engaged stakeholder dialogue pharmaceutical quality systems processes comply overall quality compliance standing frameworks help ensure consistent high level ich guidelines developed accordance ich guidelines routinely shared public health protection respect biosimilars process scientific consensus regulatory roches senior management discussed whilst protecting innovation originator industry experts working side side quality global health authorities product also firmly believe regulations management system inspected annually relating biosimilars impede rather relevant health authorities worldwide well fighting counterfeiting globally promote incentivise innovative research towards manufacturing distribution counterfeit novel medicines medicines diagnostic products criminal cros roche require employees immediately activities threaten safety patients roche collaborates governments healthcare professionals report drug safety quality issue regulatory authorities police customs services international council harmonisation technical requirements pharmaceuticals human use wwwrochecomanticounterfeiting roche people people roche people roche committed cultivating diverse talent pipeline across generations geographies functional areas expertise pillar makes roche great place work awardwinning employer year year key senior positions led people established developing region experience roche people people roche b eing science innovationdriven company really distinguishes roche people committed providing best possible working environment thrive roche start foundation respect cultivating diverse talent pipeline passionately believe company perform diversity inclusion vital foster innovation highest level maintaining caring encouraging different perspectives ideas respectful working culture taking genuine interest thinking styles business different across people fundamental part thatif get divisions world need people right everything else falls place understand differences inclusive culture also helps encourage accept leverage diversity continue focus fostering strong inclusive helps ensure lose access internal leadership culture building diverse external talent talent pipeline help people company excel everchanging business environment defined diversity inclusion means us formalised diversity inclusion roche consistently recognised one practitioners network ensure leaders best companies work honours aligned way bring commitment life awarded roche include placement several workplace great place work lists including fortune best companies list working mother magazines developing future leaders best companies list diversityincs introduced countryspecific employee value noteworthy companies propositions reflect important priorities employees site across world reflecting diversity throughout aspects business example observer panels provided global development highpotential programmes ensure diversity among assessing future leaders programmes leaders address current future business challenges across roche group need inspirational leadership across aspects diversity including generations genders geographies functional areas expertise diversity refers wide range visible invisible differences exist among people inclusion refers proactive behaviours create environment people actively included roche people people roche leadership commitments firmly believe person take genuine interest people roche deserves great leader listen carefully tell truth explain every day strive lead taking genuine interest people empower trust people make decisions example consistently discover develop potential people committed strong leadership demonstrating values strive excellence extraordinary results integrity courage passion set priorities simplify work committed increasing representation facilitate international assignments allow congratulate people job well done key leaders established developing region employees gain essential experience experience providing opportunities roche employees international assign employees work different environments ment total assignments also committed increasing representation developing regions women key leadership positions made progress goal women accounting diversity pharmaceuticals diagnostics accelerated movement talent particularly kiswahiliis programme roche leaders least leaders key leadership positions pharmaceuticals division instigated developing regions tanzanian healthcare sector leaders combines management overall leadership acceleration programme new initiative leadership development social impact see photo designed advance talent specific developing leaders attended global leadership also set targets talent scouts build regions ensure multiyear diversity development programmes include initiatives external pipelines increase representation inclusion plans led business sponsors leading leadersroche leading people significant briefings market access women people established developing across organisation roche addition leaders received compliance leadership group approximately region experience see details feedback reviews employees roche leaders travelled tanzania work diagnostics division sponsorship programme provided feedback leaders since partnership local ngos address real healthcare women key leadership positions women running successfully three challenges country improving cervical years expanded include highpotential nearly leadingroche participants reported cancer outcomes compared women switzerland people developing region experience positive change six months stating women tanzania times likely initiative members senior leadership team daily working practice closely aligned die cervical cancer disease largely preventable sponsor top talent leadership commitments whats important early detection participants managers observed increased everyone roche deserves great leader strong leadership skills six months particularly leaders found experience hugely leadership culture critical nurturing engaging increased selfawareness leadership rather impactful terms growing leadership work environment people want come management behaviour skills also teams ability identify practical women key leadership positions goal work stay longterm solutions address challenges ensure long leading changing world term sustainability programme local want leaders understand aspects fostering strong leadership culture successful leaders know must get impact participants continue support project key markets business compliance continued embed leadership comfort zone keep progressing partners remotely handing next governance people culture experience commitments within recruitment selection launched new leadership initiative focuses group roche leaders suggests takes least year living feedback performance management building skill set njiawhich means path working within country starting also continued skillbuilding programmes core understand culture competencies enhanced leadership skills employees identified potential leaders wwwrochecommateriality world health review wwwworldlifeexpectancycomworld healthreviewswitzerlandvstanzania roche people people roche personal perspective need diverse people happier engaged experiences work productivity increased significantly ways thinking arrived primary task successful integrate previously independent research roche global organisation rd efforts shanghai focus infectious diseases especially hepatitis b virus integration aligned strategy broadened pipeline talents stella xu phd site head roche structured performance management career development processes built customised innovation center shanghai plans wide range trainings help people grow professionally offer job rotations countries leadership role time reacclimate even chinese result initiatives employee language changed internet age shanghai engagement scores internal survey known impact highenergy cosmopolitan city mix geos jumped many cultures reflect diversity roche people happier engaged work innovation center productivity increased significantly role roche bridges east west science leader motivating kind management changsha capital convinced purely american swiss impact hunan province became interested science chinese way wont produce best results early age studied biophysics beijing immensely complex task drug development received full scholarship phd molecular beyond gender ethnicity nationality need biology immunology us remember diverse experiences ways thinking boarding plane two suitcases successful background helps work across dollars pocket cultures functions china employees often reluctant speak meetings accustomed finishing degree worked drug decisions made practice inclusive discovery scientist us became behaviour creating safe environment strategic consultant joined roche manager bad questions encourage people take returned china establish active role finding solutions lead team roche partnering shanghai office joined pred researchers scientist gives credibility site head roche innovation center expert every subject try shanghai nearly years abroad took keep big picture mind ask right questions communication key often join team members lunch support teams perform best listen concerns roche people people roche half employees supported preparing workplace future attracting retaining best talent every ten minutes hire one candidate based jobrelated change applications roche group candidates say evolving meet everchanging needs attracted excellent reputation great place work driven unique culture strong purpose success excellence site site may include discounts science employment benefits well buying roche nonvoting equity securities pension global development opportunities schemes health insurance childcare onsite fitness fully support fact many peoples aspirations needs whole workforce essential medical facilities flu vaccinations preventative change evolve different stages life ensure individuals feel valued respected key focus prepare workplace health screenings discounts local retailers career business environment changes teams feel benefits vast range future finding talent early career transportation workplace well taking account contractrelated changes perspectives experiences apprenticeship schemes graduate trainee half employees supported job programmes launched several new initiatives flexible benefit programmes often tailored related change workplace oftenused phrase truth help recruit identify great potential individuals needs example sites future workplace already herewe early stage development coming implemented flexible benefit programme also provide opportunities employees wait implementing change years focus extensively attracting employees prioritise certain rewards experience different role within company offering wide range attractive benefits developing talents pension company car others three months purposely nonformalised generations including flexible work environment arrangement conditions entry allowing many countries stateoftheart technology proactive inhouse approach recruitment second year applause employees gauge interest spaces business areas globally aligned group internal talent scouts programme online tool employees business fully committed roche focusing recognise directly ecards focus reflect increasing mobility building external pipelines meet future needs reward point nominations overall usage preparing workplace future staff providing access roche work covering gaps prioritised succession planning roles peer next ten years many environment anywhere anytime supporting difficulttohire current roles topeer recognitions among employees employees millennials people today device builds common hr information approach significantly contributed reducing early mids first time solution chris connects employees line dependency external recruitment agencies easy access individual benefits also five generations workforce managers hr professionals within roche also expanded availability similar sometimes different needs understanding offers broad set selfservices continuous key target roche improve totalreward statement online selfservice entire candidate experience undertaking allowing employees see full overview significant improvements increase ease compensation benefits unique application reviewing entire candidate online resource packaging employees people fiveyear goals experience pre postapplication ensure individual tailored benefits together december baseline candidates find process straightforward respectful welcoming service available total employees switzerland germany us china top quartile rewarding recognising employees go live several countries follow try strike balance highly competitive selfservice solution far base salary performancelinked rewards view rate among employees increase representation increase representation ranking overall employee also numerous benefits employees vary women key leadership roles people established engagement score measured developing region experience global employee opinion survey calculation based working days per year eighthour working days wwwrochecomemployees key leadership roles roche environment community environment community roche env ironme nt community aim minimise ecological footprint increase use renewable resources whilst continuing expand global business also seek support local communities longlasting partnerships su stainable e ne rg track goal sustainable energy consumption roche environment community environment community roche w e continued improve environmental performance significant progress improving energy efficiency safety security health environmental protection identify areas improvement recommend forms central part operations changes using database best practices important component sustainability approach employees frequently share knowledge exchange commitment businessrelated new ideas conduct regular training sessions activity striving continuous improvement wherever regional conferences workshops provide possible monitor performance regularly online tools local languages help employees ensure compliance high standards foster engagement responsibility objectives ensure processes equipment employees participated approximately stateoftheart importantly devote special hours training average attention prevention key effective hours per employee management several roche sites invested stateoftheart energyefficient infrastructure ensuring compliance fostering improvements investments allow us reduce environ policy audit chemical pharmaceutical mental footprint reduce costs diagnostic manufacturing facilities periodically increasing frequency according existing risks improving monitoring performance within roche group performed audits company global production operations roche audits assess performance exposed risks could possibly damage people legal compliance internal standards stipulate goods environment reputation audits future improvements plant management local consulting training environmental protection officers conduct frequent checks occupational health safety well professional inspections assess compliance standards risk management minimise risks safety expect contract manufacturers suppliers health environmental protection employ service providers meet standards people worldwide people security expert ensure compliance thirdparty auditors teams roche site identify risks develop managed us inspect operations suppliers mitigation plans communicate policy make recommendations improvement guidelines employees stakeholders event noncompliance may either terminate motivate implement necessary measures contract refuse renew ask improvements effectiveness management system sometimes actively support reviewed frequently employees encouraged wwwrochecomenvironment measure performance based set key performance indicators kpis aim reach least kpi wwwrochecomourshegoalsandperformance roche environment community environment community roche addition spending chf million occupational health safety employees others handle substances travel tracking tool identify assist roche environmental purposes investments safety one top priorities believe define necessary measures need know business travellers case emergency operating cost safety security totalled job urgent routine done potencytoxicity substance level trip new tool operational chf million safely primary objective keep roche exposure caused operation years accident rate rar number working days roche assessed established levels acceptable second security focus set managing material topics lost due occupational accidents per employee per exposure substances exposure levels asiaafrica security workshop held shanghai constantly aware material issues year lost time accident rate ltar determined systematically ensure site security officers asian sites regularly gather information concerning sherelated number accidents caused absence exceed established standards protection selected african affiliates discussed challenges risks opportunities roche affiliates well work per worked hours low possible overexposure must ensured engineering controls good practice three key topics regions consult listen stakeholder groups continually improving occupational new processes designed fulfil criterion prevention response counterfeiting also match stakeholder issues health safety measures set feasible existing ones modified large extent products information security including risks internal strategic priorities risks framework ambitious goals established health meet current standards containment intellectual property measures protect produce materiality matrix thus safety committees virtually roche sites engaged training adequate security measures small able identify material topics stand technical activities many sites fire process safety affiliates new group directive also issued areas interest group stakeholders according risk levels already wellestablished fire safety surveys give guidance conducting security investigations topics actively managed group performed us extended related confirmed criminal activities roche include limited climate change energy tenyear goal keep rar additional sites surveyed surveys productscounterfeiting diversion theft resources occupational mental health ltar introduced new goal carried members insurance group water roche considers material issues reduce number vehicle collisions per million professional thirdparty fire engineer employee health safety order strengthen environmental strategy kilometres next five years implementation recommendations followed knowing material issues goals reached fiveyear objective keeping rar auditing system new projects want achieve able develop clear ltar accident rate requiring fire protection installations benefit defined process create progress target low single accident resulting longer absence professional fire engineering knowhow available setting initiating action plans midterm targets lead fluctuations rar key figure roche established process safety network set new goals occupational accident profile remains consistent chemical production sites meets regularly feasible challenging areas people slips trips falls repetitive strains representing work common issues concern share best environment business also reflect several majority workrelated incidents practice recommend improvements similar sustainable development goals adopted network pharmaceutical solids formulation sites united nations see details prevention overexposure substances initiated powder handling workshop cornerstone protection health roches solids formulation managers officers held process safety management directive developed issued fiveyear goals based figures security protecting employees physical assets critical information integrity brands products principal concerns roche preventative illness rate accident rate measures priority aspects security one losttime accident rate number workrelated accidents focus implementation global working days lost per year due accidents ecobalance energy consumption water consumption general waste roche environment community environment community roche emissions water primary energy roche emissions air ecobalance landfilled waste conducting operations sustainable way water consumption leveraging modern technologies noise research pharmaceutical diagnostic competition triggers significant improvements manufacturing dependent natural resources line sustainability strategy give becoming increasingly scarce part internal stakeholders opportunity contribute commitment toward sustainable development ideas suggestions improving sustainability ecobalance holistic way measure impact emissions air contributed positive effect proactively seek employ new sustainable culture performance also raises awareness consumption energy resources despite increased number employees technologies processes minimise environmental protection encourages sustain emissions byproducts waste impact environment less roche depends ability identifying cost savings environmental business activities impact environment many today large proportion energy used roche nonrenewable resources less vulnerable protection activities ecompetition submissions different ways measure total impact using comes fossil fuels nonrenewable depleting supply constraints volatile market prices resulted significant improvements variety ecobalance metric point system allocated sources oil natural gas result areas including energy conservation waste reduction ecologically relevant parameters developed produce greenhouse gases ghg mainly co proud sustainable development decreased consumption water raw materials swiss federal office environment waste products contribute climate change achievements recognised externally reduced air pollution compliant latest guidelines metric air pollution aim maximise efficient dow jones sustainability indices ranked roche provides us global view impacting energy usage increase use sustainable industry leader environmental category winning suggestions generated earths ecosystems points added energy whilst continuing expand global business high marks climate strategy environment monetary savings chf million since related total number employees policy management reporting operational eco start programme estimation enables us monitor environmental share sustainable energy actual data goal efficiency efforts also noticed newsweek based size initiatives year impact per employee strategic fiveyear goal ranking roche th greenest company onyear cost saving potential reduce ecobalance allows worlds largest publiclytraded companies local site management freedom develop locally market capitalisation improving energy efficiency appropriate strategies objectives reducing set energysaving action plans across environmental impact local level latvian sustainability index sites include implementation organised institute corporate sustainability innovative technologies continuous upgrading ecobalance comprised responsibility gave roche silver award roche infrastructure improve energy efficiency emissions air co compared goal uruguay also recognised efforts purchase energyefficient equipment including hybrid total environmental impact per employee creating sustainable working environment cars review employee travel needs also decreased nonsustainable sustainable awarded silver leed certification sustainable change work processes complex task design leed commercial interiors rating highly regulated facilities also working efforts optimising energy consumption system focus efficient use water steady transition using sustainable energy since reducing volume consumed water well energy use leedcertified recycled total projects completed energyefficient materials equipment yield reduction approximately tonnes co emissions estimated cost saving leed leadership energy environmental design one popular green building certification programmes swiss eco chf million per year factors ecological scarcity method roche environment community environment community roche oil natural gas car fleet energy use type air travel reducing energy intensity grid electricity replacing fossil renewable energy waste district heating recently set tenyear goal consumption increase sustainable reduce energy intensity gigajouleemployee within energy use absolute terms energy consumption facilities scope purchased energy business flights slightly increased however consumed us scope flown km per headcount remained stable thanks assessment valuation impacts dependencies organisation including new buildings inaugurated expect reduce energy consumption per employee increasing employee awareness video companys six operational sites switzerland south san francisco basel approximately compared baseline levels conferencing tools used helping stabilise key objective determine approach additionally plan increase proportion businessrelated travel adds value comparison existing methodology genentechs newest building south san francisco sustainable energy used absolute use designed provide optimal working conditions terms energy consumption increased videoconferencing alternative business travel operate less energy us standard due remediation activities nutley sustainabilitya key parameter new office buildings receive leed site well increased production headcount within framework roches energyefficient gold certification see project sales grew thus decoupling energy consumption buildings focus criteria highly reflection dual efforts genentech energy growth business energysaving functional highly sustainable well high efficiency experts nearby lawrence berkeley activities resulted decrease car fuel quality urban design architecture roche brings flexlab laboratory flexlab test bed together vast array practices techniques assesses optimises building operation energy consumption terajoules skills keep energy consumption minimum realworld conditions testing various configurations measures reduce operating energy heating walls windows lighting shading heating usage videoconferencing hours power equipment integrated throughout ventilation air conditioning total scope flown kmheadcount conceptual phase finished scope structure reduce operating energy consumption basel new data centre opened energy natural capital buildings designed air leakage expected consume less energy average scope one ten multinational companies currently building reduced also includes high new european data centres roche basels newest consumption conducting detailed pilot test inform develop performance windows extra insulation walls building highrise inaugurated september gjemployee ment new natural capital protocol aims ceilings floors addition effective window earthquakeresistant highly functional scope internationally agreed harmonised approach placement provide natural light reduce sustainable topquality workspaces flexible business flights businesses systematically take account need electric lighting day layout allow approximately employees energyintensive monetary value environmental impacts approach applied new facilities across global utilities dependencies within decisionmaking andor reporting pilot assessment begun explore data collected group c ompressed air liquid nitrogen overall relationship environment along value chain addition involves detailed growth rates report constant exchange rates average roche environment community environment community roche personal perspective contributing great feeling look building building know part realisation onceinalifetime water remains constant temperature opportunity degrees celsius used cool building summer third pillar energyefficient operations sensors workstation detect markus wllner one present turn lights ventilation automatically monitoring system senior technical project manager whole building track energy usage employees encouraged think green terms reducing environmental footprint high standard inauguration ceremony held september profession constructing something possible passion magnitude onceinalifetime opportunity sustainability teamwork particularly proud building view site development plans look terms sustainability especially forward building great experience energy efficiency top priority taking role even responsibility years engineer project senior management new projects manager roche taken increasing levels responsibility roches new highrise office building first pillar sustainability minimising energy basel building height metres use installed led lights even floorswas biggest challenge ever efficient highefficiency fluorescent lamps leds need changed every team responsible technical years average significantly reduces installations building automation operating expenses waste another example minimising energy use innovative faade terms mindset sometimes helpful building triple thermal panes combined closed marathon runner project lasted almost cavity air integrated sunscreens reduce glare seven years project initiation inauguration help insulate interior heat cold final phase tough stretches quicken pace meet second pillar using sustainable sources deadlines us put long hours worked energy building heated waste heat generated led lights efficient hard colleagues resolve problems manufacturing site basel ground fluorescent lights also create unique design element finished project time budget roche environment community environment community roche limiting air emissions indianapolis branchburg switched refrigeration fire suppression suppliers sustainable source ie wind power scope achieve reductions energy saved tonnes co increased energy efficiency reduce co cdp carbon disclosure project achievements halogenated hydrocarbons tonnes roche identified global leader actions strategies response climate change awarded position global inventory climate list cdp international notfor business therefore production continues majority ghg emissions originate consumed profit organisation drives sustainable economies grow committed maintaining low transformation use energy goal furthermore roche obtained disclosure score global inventory including chugai genentech ventana level air emissions achieved date improving energy efficiency also applies ghg therefore also identified leader emissions strategy prescribes continuous improvement emissions reduction scope another initiative reduce ghg emissions dach region germany austria switzerland manufacturing sites includes using flue scope ghgs per employee tenyear period reducing use halogenated substances quality climate changerelated information gas scrubbers reduce nitrogen oxides sulphur favour use carbon offset purchasing used refrigeration andor fire suppression third successive year roche therefore dioxide various incineration freezing socalled co certificates compensate remain atmosphere long period awarded position dach climate disclosure processes reduce release volatile organic emissions alternative driving efforts time planned reduce halogenated substances leadership index compounds vocs may also reduce energy reduce emissions ghg baseline roche legacy sites use emissions air vocs decreased emissions originated within facilities excludes acquisitions including genentech disclosure score confirms understand nitrogen oxides scope amounted tonnes scope ventana working towards business issues related climate change particulates remained unchanged sulphur dioxide ghg emissions made total timelines great efforts managed incorporating climaterelated risks opportunities increased mainly due improved readings combined scope ghg emissions cut achieve reduction set core business roches performance score ventana site emissions air sites reduction achieved new goal reduce halogenated substances signals measuring verifying managing low levels means new processes implementing energysaving measures reducing roche legacy sites next five years carbon footprint activities well timing sampling amount fuel use heat cool operate continue examine alternatives work result fluctuations seen past years sites major contributors success co equivalent emissions metric tonnes scope halogenated hydrocarbons scope total scope scope total per employee scope business flights energyintensive utilities data collected group compressed air liquid nitrogen roche environment community environment community roche managing limited water resources reduce recycle purify wastewater released water treatment plants meets requirements release rivers lakes pharmaceutical industry globally poor delivered onsite treatment plant quality water resulting higher costs purification treated biologically anaerobic conditions pretreating wastewater reducing greater risk product contamination almost produces biogas mean methane content already high seek minimise chemical biotech pharmaceutical diagnostics desulphurised burnt combined contamination water discharges minimise contamination manufacturing processes involve water reagent heat power unit plant produce electricity reducing discharges toxic poorly solvent cleaning cooling agent also use water heat annually generates electricity value biodegradable substances heavy metals water energy carrier heating refrigeration eur heat byproduct used reducing generation wastewater installations heat four buildings energy worth eur treating pretreating wastewater ozone per year additionally external combustion cases non poorlydegradable water goal reduce consumption transportation aqueous solvent mixtures avoided contaminants related issues affect reputation investors per employee weighted according saving another eur per year generation increasingly showing interest water policy water stress respective region roche sites electricity sources fossil fuels reduces water usage remained relatively unchanged performance either working implementing programmes co emissions importantly process past years withdrew reduce water consumption recycle reuse produces energy needed run plant million water different sources water usage discharge water example roche basel invested changes water treatment energy user approximately consumed becoming technology save water money many chemical energy producer treated wastewater meets constituent part product vaporised reactions require cooling performed high respective requirements discharged refrigeration air conditioning plants used water withdrawn temperatures conventional laboratory condensers local river also support global efforts promote irrigation discharged salt brackish million cubic metres attached directly cold water tap consuming water protection aim reduce total wastewater waters thus lost fresh water approximately water consumed litres water per minute average toxicity selected production plants water discharged includes million cubic metres price chf per costs water used baseline chemically contaminated water sent final wastewater discharged synthesis would come chf per condenser destination via treatment plants increase treatment plant year using air coolant instead multiple approximately half water draw used due increase sites reporting million cubic metres reactions running time adds cooling circuits although water chemically parameter addition kg heavy metals organic matter considerable savings using new technology contaminated analyse directly discharging discharged operations waterways discharged waterways also reduces risks water supplies become furthermore discharge wastewater treatment tonnes disconnected spring leak pollutants comply fully relevant regulations demand fresh water increasing heavy metals discharged quickly flood laboratory including pretreatment requirements record total effective water management crucial avoid water waterways organic carbon toc discharged water following scarcity procedures place ensure treatment kilogrammes roche penzberg earned several awards processing wastewater treatment plant efficient water use business continuity water innovation environmental responsibility approximately measured toc reduction selfpowered highefficiency wastewater treatment elimination rates wastewater treatment plants plant wastewater site collected roche environment community environment community roche waste management waste tonnes sends nonrecyclable waste approximately sites total wastetoenergy plant thereby ensuring value recovered minimising waste maximising recycling general waste sites waste none sent landfill generated chemical waste roche also acting concerns impact generated pharmaceuticals environment considering construction waste entire lifecycle products two goals roche strives implement following strategy two years planning remediation first safeguard ecosystem secondly activitiesavoid reduce reuse recycle thermally kesslergrube landfill grenzach began louisville distribution facility first protect business potential longterm destroy permit landfilling last resort september construction genentech site achieve zero waste landfill financial reputational risks even inert materials slag necessary infrastructure including bypass road last years site disposed increasing incineration ash depending availability temporary shiplanding dock excavation volumes coldchain pallet shipping containers mabtherarituxan avastin herceptin lucentis suitable local wastetreatment plants may dispose contaminated soil start containing mixture cardboard styrofoam water monoclonal antibodies together nonhazardous general waste authorised landfills careful planning stepbystep approach roche filled cold packs wood pallets address generating chf billion sales roche accept landfilling chemical waste ensures safe efficient execution complex challenge site implemented comprehensive low excretion rate judged hazardous materials remediation programme keeping emissions recycling process diverting cardboard wood plastics respective authorities present significant risk minimum close dialogue maintained styrofoam previously took sewage works surface waters therefore set new goals general chemical local residents landfill volume facility delivering termed benign nature constitute environment waste reduction shipping containers recyclers approximately ally sustainable compounds reduce general waste per employee roche produces relatively low volumes chemicals shipping containers go vocational programme fiveyear period thus generates small quantities chemical employing adults special needs disassemble encourage green chemistry set reduce landfilling organic chemicals waste nevertheless continue reduce already recycle various materials technical working group presence us fiveyear period low volumes waste production biotech europe group dedicated developing accept responsibility waste generated products increases chemicalbased production currently programme receives approximately implementing best practices promote green operations including previously deposited declines roche generated tonnes usd activities financial chemistry throughout roche genentech sites landfills chemical waste general waste incinerated value recyclable materials reinvested furthermore roche environmental awareness landfilled increased largely due provide employment people disabilities chemical technology react award given continued remediation demolition cleanup activities nutley site louisville working vocational programme annually employees demonstrate programmes activities cleanup soils made tonnes generated enhance work stream process number environmentally friendly approaches former site nutley completed yearend construction demolition waste comprised shipping containers maximised recycling chemical synthesis cleanup groundwater underway take tonnes sites south san various site waste streams louisville site several years complete plan divest francisco grenzach main contributors property retain responsibility environmental cleanup post divestment roches remediation project nutley clear commitment longterm value site community roche environment community environment community roche employees raised funds give partnering support local communities record participation employees sites raising children around world better life approximately chf million majority philanthropic engagement funds used provide children malawi education school supplies water sanitation roches commitment malawi spans years roche worked school create wellbeing helped support children programme offering education topics hiv education remaining funds collected aids prevention healthy lifestyle management roche committed sustainable philanthropic five years widespread flooding pakistan childrens walk used support different childrens personal finance skills activities span community involvement roche helped open new primary school programmes local communities humanitarian projects science education art jacobabad city particularly hardhit roche operates around world another important initiative genentech culture goal establish longterm roche helped build equip operate school foundation provides support eastside partnerships focusing projects add collaboration citizens foundation roche also supports several initiatives college preparatory school palo alto california lasting value society local nonprofit organisation focusing improving provide accessible highquality holistic education goal make quality education available education students already disenfranchised young adults one programme children living difficult neighbourhoods responding natural disasters enrolled girls school aims innovative maharishi institute south th year row every eastside graduate following natural disasters roche works local increase support education equality africa provides free tertiary education young gone fouryear college partners provide immediate support essential country people experienced particular hardship donations medicines longterm support help communities rebuild another important initiative reporting year disaster relief following floods malawi nepal struck devastating earthquake january according united nations killing injuring thousands displacing millions childrens fund people affected response roche donated vials roche made financial donation support disaster rocephin antibiotic treats wide range relief efforts included distribution mosquito roche made financial donation support disaster relief efforts malawi included distribution mosquito nets infectious diseases serious forms nets protect displaced people malaria tuberculosis meningitis roche india used diseases local stock provide immediate help additionally chugai donated jpy million japan platform supporting education emergency aid organisation roche longstanding philanthropic commitment malawi southeast africa since supported education programmes hivaids natural disaster roche reacts orphaned children year employees get involved raising money participating immediate needs provides roche childrens walk sustainable help wwwrochecomphilanthropy wwwrochecomchildrenswalk roche environment community environment community roche next generation scientists helping students unleash potential genentech employee volunteers serve coaches mentors weekly tutoring programme researchbased healthcare company science communicate results scientific report technology core poster english final round ten supported multiple programmes promote bestperforming classes invited special event helix cup annual science competition helix cup part genentechs futurelab interest disciplines among young people roche basel give innovative live presentation focuses realworld challenges associated programme multiyear partnership ssfusd many years time seek inform results experiences class delivering healthcare medicine programme involves major commitments including educational career opportunities creative imaginative convincing presentation needed challenge gives students opportunity construction usd million standalone areas selected expert jury awarded science deepen understanding key concepts biotech teaching facility ssf high school week abroad science engaging format also helps campus slated break ground also includes building foundation science technology develop skills creativity problemsolving creation stateapproved high school biotech providing realworld science skills enabling classes participated programme teamwork curriculum college scholarships promising continued education careers biotech hope top ten travelled basel display students pursuing degrees science technology help grow next generation innovators science scientific knowledge enthusiasm creativity students participated helix cup engineering math fields move helix cup projects conducted winners class g kantonsschule zug received designing solutions potential barriers switzerland us respectively leading weeklong science trip uk visited delivering medicines remote areas keeping addition serving coaches employees acted examples efforts support young scientists roche uk site creativity workshop medicine cool delivery three rounds mentors weekly tutoring programme local science students attended lectures london competitive challenges top teams elementary school students advisors ssfusd experimenting science school hygiene tropical medicine school came genentechs ssf site compete science teachers even donated hard work established science move set royal society chemistry visited several fourth final challenge determined projects improve playgrounds facilities hopeful discoverers across switzerland open renowned science museums sponsored roche winning team ssf schools secondary classes project culminates run simplyscience foundation science biannual competition engages young people move initiative scienceindustries genentech employees also get involved fun genentech employees science teamwork fun programme fosters representing swiss business association volunteer coaches support students throughout students interest biology science identifies chemical pharmaceutical biotech industries competition encouraging directing teams volunteered futurelab class greatest dedication commitment explaining genentech serving fields solving healthcare challenges positive role models sharing inspired programmes first year genentech long history supporting science career journey competition challenges broad range abilities education south san francisco ssf students explore various experiments theories main company site located genentech showcase scientific communication introduced helix cup handson competition skills traditional innovative ways science designed bring science alive students move consists three phases phase one south san francisco unified school district two goal conduct two biological ssfusd biochemical experiments laboratory wwwrochecomscienceeducation wwwgenecomgoodgivingfuturelab roche corporate governance corporate governance roche cor porate gove r nance roches corporate governance aims safeguarding sustainable interests company years r unning roche ranked sustainable healthcare company dow jones sustainability indices roche corporate governance corporate governance roche annual general meeting annual general meeting principles board directors roche committed serving stakeholders governance requirements particular board directors board committees basis successful implementation applicable laws swiss stock exchange six swiss board committees presidium nomination committee commitment corporate governance principles exchange directives swiss code best accordingly put focus business activities practice corporate governance promulgated remuneration committee sustainable value creation innovation swiss business federation economiesuisse audit committee prescribe management culture conforming companys internal governance framework recognised standards good corporate governance particularly articles incorporation bylaws corporate governance sustainability committee policy transparent communication embodies principles needed ensure companys businesses managed supervised corporate executive committee strong board directors represents manner consistent good corporate governance corporate executive interests shareholders stakeholders including necessary checks balances coo coo general committee ceo cfo hr highly skilled managers act integrity pharma diagnostics counsel extremely important printed annual report contains selected links roche website wwwrochecom readers th consecutive year roche thus provided snapshot company enlarged corporate executive committee enlarged corporate recognised dow jones sustainability indices reporting date also directed sources gred pred partnering communications group leader sustainability within consult time uptodate executive committee pharmaceuticals biotechnology life sciences information corporate governance roche chugai industry sustainability core business whereas annual report covers single financial practices award reflects commitment year ending december website contains running business way ethical responsible information permanent nature well creates longterm value stakeholders latest roche news companys articles incorporation bylaws curricula vitae corporate governance report sets members board directors corporate structures processes rules roche takes executive committee published website basis wellfunctioning corporate governance roche complies relevant corporate details please refer following report wwwrochecomgovernance roche corporate governance corporate governance roche board directors board directors th annual general meeting agm march forthcoming agm board directors board committees roche holding ltd march shareholders board directors nominates chairman board committees presidium nomination committee reelected christoph franz chairman remaining members board directors board directors reelection announced may deanne remuneration committee julius member board directors audit committee furthermore agm reelected andr hoffmann since decided stand reelection pius baschera john bell paul bulcke deanne julius announced december addition beatrice corporate governance sustainability committee andreas oeri severin schwan peter r voser weder di mauro member board since beatrice weder di mauro elected bernard poussot decided stand reelection richard p lifton new members board board nominates mrs julie brown mrs claudia directors term one year provided sssmuth dyckerhoff election new members articles incorporation board directors agm composition name year birth first elected addition agm elected christoph franz moreover board directors nominates board directors dr christoph franz c e chairman andr hoffmann peter r voser bernard poussot christoph franz andr hoffmann peter r voser andr hoffmann c e vicechairman members remuneration committee bernard poussot reelection richard p representative shareholder group lifton election members remuneration pooled voting rights organising meeting immediately following committee agm dr andreas oeri e agm board directors determined representative shareholder group structure composition remaining board directors nominates bdo pooled voting rights committees shown see also pages ag independent proxy period prof dr pius baschera e board directors corporate conclusion ordinary annual prof sir john irving bell b e executive committee general meeting shareholders election paul bulcke b e agm dame deanne julius b e prof dr richard p lifton e bernard poussot c e dr severin schwan f peter r voser c e prof dr beatrice weder di mauro b e secretary dr gottlieb keller board directors honorary chairman dr fritz gerber board directors corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson roche corporate governance corporate governance roche corporate executive committee corporate executive committee corporate executive coo coo general committee ceo cfo hr pharma diagnostics counsel memberships corporate executive committee remained unchanged enlarged corporate executive committee enlarged corporate information member corporate gred pred partnering communications executive committee executive committee enlarged corporate chugai executive committee listed see also pages board directors corporate executive committee composition name year birth position since corporate executive dr severin schwan ceo roche group committee daniel oday coo division roche pharmaceuticals roland diggelmann coo division roche diagnostics dr alan hippe chief financial officer silvia ayyoubi head group human resources dr gottlieb keller general counsel enlarged corporate osamu nagayama chairman ceo chugai executive committee dr michael varney head genentech research early development gred prof john c reed head roche pharma research early development pred dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey since chief compliance officer dr urs jaisli roche corporate governance corporate governance roche roche pharma incl genentech pharma chugai professional diagnostics molecular diagnostics diagnostics group structure shareholders tissue diagnostics diabetes care roches operating businesses organised two note financial statements roche composition divisions pharmaceuticals diagnostics holding ltd significant shareholders pharmaceuticals division comprises two business addition significant shareholders published segments roche pharmaceuticals chugai whereas relevant webpage disclosure office six genentech former third segment exchange regulation wwwsixexchangeregulationcom capital structure integrated roche pharmaceuticals diagnostics enhomepublicationssignificantshareholdershtml division consists following four business areas diabetes care molecular diagnostics professional andr hoffmann vicechairman board diagnostics tissue diagnostics directors chairman remuneration information roches capital structure provided including provisions protecting interests committee andreas oeri member board finance report notes financial statements ofnes holders described articles business activities carried group directors chairman boards corporate roche holding ltd additional details incorporation roche holding ltd subsidiaries associated companies detailed governance sustainability committee serve contained articles incorporation information roche holding ltd significant respective capacities board roche holding ltd information debt instruments subsidiaries associated companies including committees representatives shareholder issued outstanding bonds provided company name listing information domicile share group pooled voting rights receive movement recognised amounts last finance report note roche group capital equity interest listed finance remuneration set forth remuneration report three financial years detailed finance consolidated financial statements debt report note roche group consolidated finance report note report notes financial statements roche financial statements subsidiaries associates roche group consolidated financial statements holding ltd information employee stock options provided related parties exception finance report note roche group jrg duschmal works postdoc roche company share capital chf consolidated financial statements equity major shareholders listed finance report relationships exist shareholders divided fully paid bearer shares compensation plans including detailed notes roche group consolidated pooled voting rights nominal value chf information stocksettled stock appreciation financial statements equity attributable roche restrictions exercise voting rights rights ssars plan roche restricted stock shareholders related parties pages crossshareholdings shares upon deposit shares voted unit plan roche performance share plan without restrictions roche connect roche option plan authorised conditional capital roche issued options apart employee stock options described finance report addition nonvoting equity securities note roche group consolidated financial nes issued bearer form statements equity compensation plans form part share capital confer voting options issued connection debt instruments rights nes confers rights one share participate available earnings neither options awarded employees liquidation proceeds following repayment share debt instruments issued capital roches nes rights pertaining thereto effect roches share capital wwwrochecomarticleofincorporation roche corporate governance corporate governance roche board directors board directors board committees board committees presidium nomination committee board directors corporate remuneration committee audit committee executive committee corporate governance sustainability committee information member board directors exception severin schwan none corporate executive member corporate executive members board directors office end corporate executive committee committee committee listed pages members member roches corporate board directors age limit restriction executive committee served executive capacity term office curricula vitae current group subsidiary three financial former members last five years years preceeding current reporting period bodies information including information lack existing business connections described committees report operating financial risks risk years first election board members group subsidiary independent authorities responsibilities defined detail management system additional positions memberships activities bylaws board directors roche group established risk management available continuously updated internet principles governance principles process covering entire company system delegation competence reservation powers committees chaired independent place identify manage type risks rules pursuant article para point vegv management group companies directors potentially affecting business including economic number permitted activities board executive bodies company include economic environmental social impacts risks directors corporate executive committee environmental social topics principles according bylaws board directors opportunities containing stakeholder input members outlined articles together internal organisation board board meeting may convened without board directors highest governance incorporation roche holding ltd directors division authority responsibilities chairman present request members body involved roches risk management policy sets board management remits roche board meets year assess approach accompanying responsibilities since annual general meeting elects board committees information control chairmans performance meeting pharmaceuticals diagnostics divisions members board directors chairman mechanisms available board dealings attended chairman chaired global functions conduct formal risk assessment board directors members corporate management governed bylaws vicechairman process least year must develop remuneration committee annual basis risk plans material risks elections nominee voted separately board directors roche holding ltd part management information system mis monitored deviations reviewed regular see articles incorporation roche organised ensure group conducts board directors informed performance dialogues consolidated group holding ltd minutes th annual businesses responsibly focus longterm important issues sales performance etc monthly risk report including target risk profile discussed general meeting roche holding ltd held value creation end roche board basis board access electronic information corporate executive committee approved march delegated certain responsibilities several committees platform provides timely information together group business plan material composition chairpersons december board directors boards committees risks reviewed board yearly basis system controls set forth process subject regular reviews findings presented audit committee wwwrochecomboardofdirectors wwwrochecomexecutivecommittee board directors established system full board effectiveness risk management wwwrochecomarticleofincorporation controls continuously monitored process monitored group risk advisory wwwrochecomannualgeneralmeetings audit committee corporate governance team overall process regularly reviewed wwwrochecomarticleofincorporation sustainability committee board external auditors wwwrochecomcommittees directors consists following elements details risk management including risk wwwrochecomarticleofincorporation factors risk management policy see risk roche corporate governance corporate governance roche management compliance website efficiency processes controls action plans october october board directors regularly conducts financial risk management specifically described implement necessary changes enhancements blackout periods changed chairman assessment selfassessmentassessment third parties finance report developed together businessauditee board directors circumstances warrant via electronical survey personal interviews system internal controls financial reporting tracked completion performance independent assessment see pages finance report statutory auditors see board directors met meetings third party conducted internal audit chief compliance officer compliance officers generally hours length including group audit reports general counsel subsidiaries see fullday meeting addition day visit members corporate executive committee direct access gives regular briefings audit safety health environmental protection major subsidiary board committees met maximum ordinary notice period twelve months committee corporate governance department follows changeofcontrol clauses sustainability committee ongoing activities corporate sustainability committee presidium board directorsnomination employment contracts audit reports chief audit risk advisory science ethics advisory group seag committee meetings approx hours executive attends audit committee partly issues relating genetics genetic engineering including telephone conferences management contracts fall within corporate governance sustainability remuneration committee meetings approx scope subsection annex six directive committee meetings external auditors members corporate executive committee hours information relating corporate governance group audit independent appraisal function invited attend meetings board audit committee meetings approx hours evaluates reviews groups activities directors report person agenda service management annual audit plan items concerning situation warrants corporate governance sustainability yearly defined focus areas eg emerging members enlarged corporate executive committee meetings approx hours markets thirdparty management validated committee may also invited attend board senior management presented audit committees invite chairman board committee roche group committed corporate executive committee members deliver board board committees attendance maintaining high standard internal control reports committee meetings may elect throughout worldwide operations management commission independent expert reports call corporate presidium governance responsible assessing business risks services consultants nomination remuneration audit sustainability aspects operation implementing board committee committee committee committee effective efficient processes controls whilst year several blackout periods imposed number meetings ensuring compliance internal external senior employees prohibited ch franz rules regulations trading company stock following blackout hoffmann conducting operational audits group audit periods effect p baschera determines managements response risks december january j bell surrounding business processes systems april april p bulcke evaluates appropriateness completeness june july julius rp lifton b poussot wwwrochecomriskmanagementandcompliance schwan additional information provided finance report note roche group consolidated financial statements risk management oeri pr voser wwwrochecomenvironment b weder di mauro wwwrochecomsustainability member committee wwwrochecomethicalconflicts invited guest board committee meetings figures indicate actual length meetings include directors extensive premeeting preparations postmeeting remuneration committee members recuse deliberations decisions matters affect interests followup activities roche corporate governance corporate governance roche remuneration shareholdings loans participatory rights shareholders details regarding remuneration shareholdings rules aol participatory rights shareholders articles incorporation loans content method determining content board cec defined roches articles incorporation shareholders representing shares nominal compensation shareholding programmes rules principles roche shares issued bearer value least chf million request basic principles elements compensation applicable performance restrictions admission annual general placement items agenda annual shareholding programmes serving former related pay meetings exception shares must general meeting must done later members board directors corporate rules principles deposited within specified period date days date meeting executive committee together description allocation equity securities meeting admittance card must issued authorities procedure determining convertible rights options shareholders name provided rules issue instructions set forth separate remuneration report additional amount payments articles incorporation shareholder elect independent proxy rules electronic pages finance report notes members executive represented third party annual participation agm laid roche group consolidated financial committee appointed general meeting corresponding invitation agm statements equity attributable roche shareholders vote pay general regulated articles incorporation related parties pages listed meeting shareholders articles incorporation contain restrictions note financial statements roche holding rules loans credit facilities exercise voting rights quorum ltd board executive shareholdings postemployment benefits requirements stipulated conformity rules vote pay swiss code obligations following rules remuneration shareholdings agm loans board directors board corporate executive committee cec set forth articles incorporation aoi dr andreas oeri chairman corporate governance sustainability committee wwwrochecomarticleofincorporation roche corporate governance corporate governance roche change control defensive measures go beyond legal requirements company formal policy governing attestation services comfort letters consents engagement statutory auditor nonaudit consultation services policy prohibits certain services provided permits certain services articles incorporation contain provisions would terminated event acquisition tax services include services respect limits agreed audit committee mandatory bid rule swiss law applies vesting period restrictions preexisting awards compliance tax returns tax advice except potential nonaudit service engagement reviewed would removed options could services related audit tax policy authority proceed changeofcontrol clauses exercised immediately given components remuneration based roche nes services include advice relating process improvements regulations trainings relationship statutory auditors relationship independent proxy annual general meeting roche holding ltd kpmg received following remuneration march shareholders voted appoint services statutory auditors roche holding ltd recent years bdo ag served independent rules issue instructions kpmg ag kpmg statutory auditors based auditors roche companies proxy annual general meeting march independent proxy rules electronic existing legal requirements swiss code including chugai shareholders elected bdo ag independent participation agm laid obligations article concerning maximum proxy period conclusion corresponding invitation agm term office seven years auditor charge ordinary annual general meeting regulated articles incorporation ian starkey replaced predecessor john morris millions chf shareholders bdo ag paid services auditorincharge starting business year auditing services according expenditure totalling chf information long auditors auditorin auditrelated services chf charge serving capacities provided accounting statutory auditors participate assurance audit committee meetings prepare written tax services oral reports results audits audit services committee oversees assesses auditors total makes recommendations board information authorities responsibilities audit statutory auditors elected year committee see article bylaws annual general meeting statutory auditors participated meetings audit committee auditing services provided legally required reports statutory auditor consolidated auditrelated services include assurance financial statements financial statements accounting services provided auditors found pages respectively necessarily provided statutory auditor years finance report services include audits pension funds employee benefit plans internal control reviews wwwrochecomarticleofincorporation roche corporate governance corporate governance roche information policy chief compliance officer compliance officers network provided articles incorporation relevant information documents including corporate notices published swiss official media releases investor updates presentations gazette commerce daily newspapers analyst investor conferences available chief compliance officer compliance group code conduct reference documents designated board directors basler zeitung internet publications ordered officers network committed ensuring furthermore serve platform ideas finanz und wirtschaft lagefi le temps neue email fax telephone roche group code conduct consistently suggestions concerning documents zrcher zeitung baselwebmasterrochecom complied throughout roche group also tel serves contact person shareholders employees addition roche established business ethics roche reports halfyear fullyear results fax customers suppliers general public issues incident reporting beir system enables business reports published print andor online relating implementation compliance chief compliance officer capture track formats media events addition detailed contact address investor relations code employees parties monitor alleged violations initial reports first thirdquarter sales figures published f hoffmannla roche ltd investor relations become aware violations roche group code local compliance officers resolution year april october current list group finance basel switzerland conduct bring attention business ethics incidents recorded system publication dates available english tel managers supervisors local compliance local management receives specific german internet fax officer report chief compliance officer concrete information alleged violation urs jaisli direct phone number roche group code conduct one certain pre additional information including details specific email ursjaislirochecom disclosures defined categories corporate governance contact persons available internet treated confidentially addition end sustainability committee audit committee employees may anonymously report irregularities board directors informed substantial complaints mother tongue via speakup violations managements corrective actions made line starting december new compliance tool group level socalled roche group code chief compliance officer reports general conduct help advice line introduced counsel also submits regular reports strives provide guidance case questions corporate governance sustainability committee uncertainties interpretation roche audit committee board directors nonapplicabilitynegative disclosure wwwrochecomarticleofincorporation wwwrochecommedia wwwrochecominvestors wwwrochecominvestorscontacts expressly noted information contained provided six swiss exchange corporate wwwrochecomcodeofconduct mentioned herein either nonapplicable governance directive commentary thereto wwwrochecomriskmanagementandcompliance omission construed negative declaration roche remuneration report remuneration report roche remuneration report roche committed compensation system balanced performanceoriented aligns interests employees owners company employees satisfied benefits according global employee opinion survey roche remuneration report remuneration report roche principles roches success depends substantially expertise compensation packages competitive motivation performance employees structure individual components conviction forms basis compensation policy regularly benchmarked swiss european international criteria remuneration guidelines roche aims remunerate employees fairly underlying principles also subject transparently line market conditions regular outside comparisons toenable participate appropriately companys success pursue goal providing however compensation policy one factor competitive performancebased compensation safeguarding roches future success see wwwrochecomrewards another key element strive balanced mix fixed variable corporate culture offers employees conditions compensation components geared employees make best possible contribution position management responsibility shared corporate goal improving healthcare patients includes sound value system variable components intended create based integrity courage passion see additional financial incentives achieve corporate wwwrochecomlivingourvalues time goals keep innovation consistently high decentralised management approach plays level increasing value company major role wide scope individual decision creates stakeholder groups making respectful interactions openness diversity time order allow employees managers wideranging training development opportunities participate companys business success attractive working environment employees adequate compensation measures key motivation loyalty organisation solely incentives take form annual bonus payments based terms compensation longterm sharebased programmes roche committed fair balanced performance global company like roche marketcompetitive based compensation policy links employees remuneration plays key role along performance interests various stakeholder groups based transparent compensation structure ensure roche remuneration report remuneration report roche remuneration decision process consulting firm pricewaterhousecoopers pwc assists meeting approval implementing ordinance roche performing market comparisons excessive compensation listed corporations advising remuneration committee information verordnung gegen bermssige vergtungen bei approval framework remuneration committees remit powers brsenkotierten aktiengesellschaften vegv procedures making remuneration decisions general meeting shall vote annually binding found bylaws roche board directors effect approval remuneration overview upon recommendations remuneration articles incorporation also board directors resolved board year remuneration committee roches committee outlined sections principles directors corporate executive committee board directors meets least twice decides governing specific remuneration components see details see remuneration board members members remuneration committee tracks market data groups corporate executive committee salaries leading global pharmaceuticals since total aggregate amounts based terms performance share plan psp awards companies major swiss companies decisions submitted general decided annually board directors acting reports findings full board external remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec peer set ceo abb abbott laboratories base payremuneration actelion abbvie bonus c credit suisse amgen stocksettled stock remuneration committee lafargeholcim astellas appreciation rights annual general nestl astrazeneca restricted stock units meeting nobel biocare bayer roche performance share plan board directors upon sonova bristolmyers squibb recommendation straumann eli lilly remuneration committee swiss glaxosmithkline decisions pension c remuneration committee ubs johnson johnson zurich insurance merck co novartis peer set pfizer sanofi takeda peer set abbott laboratories abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline market comparison companies salary assessment johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compared pharma peer set abb actelion credit suisse lafargeholcim nestl nobel biocare sonova straumann swiss ubs zurich insurance major swiss companies wwwrochecomarticleofincorporation wwwrochecomarticleofincorporation roche remuneration report remuneration report roche procedure submitting total board retrospective approval approval total remuneration annual general financial year financial year executive remuneration shareholder approval total aggregate bonus amounts corporate meeting annual general meeting executive committee chairman board retrospective year annual general meeting agm directors financial year ended shareholders approve total remuneration submitted retrospectively ordinary agm board directors corporate executive separate binding approval chairman bod c c committee decided board directors bonus financial year total amount bonus remuneration committee board directors prospective approval respectively board executive aggregate remuneration corporate executive committee cec cec submitted prospectively agm separate bonus financial year total amount bonus according approval agm roche binding approval period two committed obtaining separate binding ordinary agms prospective shareholder approvals total remuneration paid board directors corporate executive committee follows board directors bod including c bod aggregate total remuneration agm agm base payremuneration base payremuneration corporate executive committee cec including ceo aggregate total remuneration agm agm cec base pay base pay ssars stocksettled stock appreciation rights ssars psp performance share plan psp indirect benefits indirect benefits mr andr hoffmann chairman remuneration committee agm agm agm roche remuneration report remuneration report roche variable sti bonus base salary lti indirect benefits employer contribution stocksettled stock pensions insurance contributions appreciation rights roche ahvivalv performance share plan roche connect remuneration components remuneration restricted stock units tax consulting services components expense allowances overview remuneration elements align interests roche employees others remuneration members board shareholders childrens schooling costs directors corporate executive committee foreign tax obligation composed following elements lti remuneration components intended fixed sustainably homogenously longterm oriented fixed base salary complemented annual align managements interest shareholders variable bonus shortterm incentive sti holders nonvoting equity securities give perennial variable remuneration elements participating managers additional incentive ssars psp rsus longterm incentive lti achieve continued value growth form long term total shareholder returns creating value remuneration components linked roche investors management benefits well base pay fixed qualitative individual functional performance employees performance companys financial added longterm value created investors base pay cash payment determined objectives competitive reasons roche performance commercial success thus management penalised receiving less position based salary market data leading disclose individual performance objectives global pharmaceuticals companies see footnote members corporate executive committee major swiss companies see footnote reflects individuals abilities experience december end reporting year performance time pay adjustments likewise january following reporting year remuneration linked individual performance take account committee decides bonuses amounts prevailing market conditions companys payable chairman board members overall financial situation corporate executive committee respect composition remuneration board directors corporate executive committee current reporting year based performance remuneration committee makes reviews aforementioned objectives annual remuneration elements description c bod ceo cec final decision individual base pay paid time remuneration committee also decides base pay monthly payment q uarterly chairman board directors members form bonuses awarded ie cash payments remuneration see payments corporate executive committee andor blocked nonvoting equity securities andor bonus annual payment years years cash remuneration members board blocked shares see blocked shares blocked shares pensions etc see bonuses variable stocksettled stock appreciation rights perennial bonuses annually awarded individual variable remuneration elements contributions value creation business year stocksettled stock appreciation rights ssars stocksettled stock see meant incentive strive outstanding plan introduced establishing uniform appreciation rights results create new business opportunities system remuneration throughout roche ssars ssars bonus amounts linked group divisional entitle holders benefit financially increase performance share see years profits sales growth operating profit capital value roches nonvoting equity securities plan psp blocked shares charge opac earnings per share nonvoting grant date exercise date restricted stock see per replaced per replaced equity security nes growth product development ssars granted cec members vest together units rsus ssarspsp ssarspsp pipeline achievement measurable three years exercised within roche remuneration report remuneration report roche seven years grant date unexercised ssars rsus remuneration component continued psp historical performance indirect benefits lapse without compensation since fair value authortised roche employees award originally targeted nes shown ceo ssars calculated grant date using chairman respectively members corporate trinomial model american options details performance share plan psp variable executive committee additionally received indirect see members corporate executive committee benefits payments pension funds mgb stiftung members senior management currently der f hoffmannla roche ag fr mitarbeiter ssar awards allocated individually individuals worldwide participate gewinnbeteiligung als ergnzung der beruflichen remuneration committees discretion performance share plan psp established vorsorge ie employee profitsharing foundation periods three years based supplementing occupational pension benefits restricted stock units variable threeyear comparison total shareholder insurances roche connect see payments restricted stock units rsusrights receive non return tsr peer companies see footnote foreign tax obligation tax consulting services voting equity securities andor shares three annual expense allowances shown year vesting period plus value adjustment respective year psp consists three individual members corporate executive amount equivalent sum dividend paid overlapping performance cycles new cycle committee received payments schooling costs vesting period attributable number starting beginning year cycle children nonvoting equity securities individual finishing end year award grantedwere introduced new remuneration component partially replacing three overlapping ssars rsu awards allocated individually performance cycles psp psp weighting fixedvariable remuneration components target percentage total remuneration remuneration committees discretion psp psp closed vested recipient three years thereafter december resulting nonvoting equity securities may remain chairman blocked years vesting psp cycle targeted nes blocking periods interests rsu recipients awarded psp per december board directors shall aligned companys longterm success targeted nes awarded commitment employees company corporate executive shall increased plans key performance metric award committee including ceo total shareholder return tsr calculated value ssar awards reduced threemonth moving average rate start balance awarded form rsus end performance cycle fixed variable payment performance share plan rsus remuneration component determined board directors annual corporate executive committee replaced basis acting upon recommendations awarding corresponding psps therefore remuneration committee variable longterm incentive programmes corporate executive committee comprise psp awards ssars roche remuneration report remuneration report roche ratio variable remuneration components relative fixed base pay corporate executive changes respect remuneration comprise psp ssars awards committee components structure lti simplified calculation psp values comparison competitors companys ratio variable remuneration components bonuses ssarsrsus psp relative value fixed base pay corresponding reporting year newly based performance reflected share price fair value grant bearer share prices averaged total shareholder return shall incorporated sti lti three months october december much deeply corporate executive criteria bonus ssarsrsus psp prior start performance cycle committees remuneration individual target value ssars calculated per target amount roche securities rsus entire psp three years cycle starting psp awards remuneration minimum distribution one year instead former component reserved corporate maximum calculation three cycles corresponding executive committee enlarged corporate performance criteria group objectives group value development value development determined distribution reporting year ie cycles disclosed executive committee longterm divisional business determined performance performance starting target remaining cycle psp based incentive programmes previous psp performance individual plus value adjustment psp cycle plus actual value psp vesting year participants comprise ssars rsus objectives considering profit dividends nes value adjustment dividends awards sales growth opac operating grant nesbearer shares rsus corporate executive profit capital charge grant committee replaced awarding additional details please refer following earnings per share nes group performance tsr psps therefore future longterm incentive sections remuneration report growth product development relation tsr performance programmes corporate executive committee pipeline peer set tsr definition see split group objectives na b individual objectives na assessed consideration performance competitors macroeconomic development based annual base pay measured january first year cycle see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings roche remuneration report remuneration report roche remuneration board directors resolution approval remuneration chairman board directors members board directors decided remuneration committees discretion taking account market comparisons remuneration form cash payments annually tracked market data directors pay leading global pharmaceuticals companies see footnote major swiss companies see footnote assisted consultancy pwc previous year board directors separately submit total aggregate bonus chairman board directors general meeting financial year retrospectively binding approval maximum amounts total aggregate remuneration board directors period ordinary general meeting ordinary general meeting tabled previous year general meetings prospectively binding approval see amount remuneration members board directors members board directors received remuneration additional compensation form quarterly fixed cash payments shown list members positions committee memberships chairmanships see detidua remuneration members board directors table board activities roche paid legally required employers contributions total chf chf swiss social security programmes providing retirement disability unemployment benefits ahvivalv members board directors beside legally required contributions separately stated chairman board directors basic remuneration board directors excluding chairman remained unchanged since remuneration members board directors remain unchanged exception chairman board directors bonus form blocked shares severin schwan executive member board members board directors awarded shares nonvoting equity securities ssars rsus loans credits granted members board directors capacity member international advisory council iac chugai pharmaceutical co ltd andr hoffmann received honoraria amounting total usd chf detidua remuneration members board directors chf additional compensation additional special basic remuneration committee memberschairs compensation total remuneration ch franz chairman see total remuneration paid chairman board directors hoffmann vicechairman see p baschera j bell p bulcke julius rp lifton b poussot oeri schwan see highest total remuneration paid severin schwan member corporate executive committee remuneration received primary function ceo reflected total remuneration corporate executive committee pr voser b weder di mauro total exception members presidium chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december additionally employer contribution ahvivalv totalling chf including chairman paid form part compensationroche remuneration report remuneration report roche remuneration members board directors chf additional compensation additional basic remuneration committee memberschairs special compensation total remuneration ch franz chairman see total remuneration paid chairman board directors hoffmann vicechairman p baschera j bell p bulcke julius rp lifton na na na na b poussot na na na na oeri schwan see highest total remuneration paid severin schwan member corporate executive committee remuneration received primary function ceo reflected total remuneration corporate executive committee pr voser b weder di mauro franz b humer retired wm burns retired ad levinson retired total prorated remuneration serving chairman board period january march amounting chf bonus award chf form shares blocked years calculation number shares based share price date transfer april calculation value consideration reduction value due blocking period years reduced market value employer contributions employee stock purchase plan roche connect prorated period january march amounting chf payments tax consulting services chf plus prorated remuneration pension fundsmgb stiftung der f hoffmannla roche ag fr mitarbeiter gewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits chf additionally employer contribution ahvivalv chf chf paid form part compensation franz b humer received advisory capacity presidium planned years chf total amount paid franz b humer received honoraria amounting total usd chf serving member international advisory council iac member board directors chugai pharmaceutical co ltd starting april prorated remuneration period january march prorated remuneration period january september without amount footnote since activity member board additionally employer contribution ahvivalv totalling chf including chairman paid form part compensation detidua total remuneration paid chairman board directors chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowances total prorated remuneration member board directors period march december chairman board directors period march december form shares blocked years calculation number shares based share price date transfer april respectively approval agm agm calculation value consideration reduction value due blocking period years reduced market value approved agm submitted shareholder approval agm including employer contribution social securities beneficial parts detidua total remuneration paid chairman form bearer shares blocked years payable board directors april put shareholder binding vote chairman christoph franz received total ordinary annual general meeting agm remuneration shown remuneration committees bonus proposal adopted chairmans total remuneration contained late respect financial year total remuneration board directors total remuneration paid board member board directors member directors international advisory council iac chugai calendar year members pharmaceutical co ltd addition chf board directors received remuneration employers contribution paid ahvivalv including bonuses totalling chf chf tax consulting services paid chf excluding additional employers last time contribution paid ahvivalv totalling chf chf former member board directors william form part compensation burns received honoraria amounting total usd chf capacity remuneration paid former members member international advisory council board directors iac chugai pharmaceutical co ltd former member board directors franz b humer received honoraria amounting additional remuneration paid total usd chf serving mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits additionally employer contribution ahvivalv chf chf paid form part compensation detidua detiduaroche remuneration report remuneration report roche board remuneration subject approval table total remuneration paid chairman submission boards total aggregate severin schwans remuneration shown annual general meeting board directors board future remuneration binding shareholder vote receives function ceo member directors submit remuneration committees board directors proposes corporate executive committee included submission chairmans total aggregate bonus proposal adopted late chairman ordinary agm approve board remuneration totalling part corporate executive committees bonus binding vote annual general board christoph franz respect chf excluding legally total remuneration meeting financial year payable april excluding legally required employers contributions ahvivalv remuneration chairman board required employers contributions ahvivalv excluding bonuses period ending directors includes bonus award chf shareholder binding vote ordinary ordinary agm form shares blocked years shown annual general meeting agm prospective approvals boards total aggregate future remuneration chf retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount proposal agm agm agm period period period aggregate amount aggregate amount aggregate amount agm agm agm agm agm agm financial year financial year financial year total aggregate amount proposal approval total aggregate amount proposal approval approved agm approved agm excluding legally required employers contributions ahvivalv excluding bonuses excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based share price date transfer april approval agm calculation value consideration reduction value due blocking period years reduced market value reconciliation reported remuneration comparison ordinary agm submitted shareholder approval agm includes franz b humers bonus former chairman shareholders approved remuneration ordinary agm actual remuneration amounted members board directors chf excluding legally required ordinary agm approved board remuneration employers contributions ahvivalv totalling chf excluding excluding bonuses legally required employers contributions ahviv alv excluding bonuses period ending ordinary agm prospectively approved total remuneration members board directors comparison actual total payments made chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm approval yet maximum total remuneration approved agm required actual total remuneration paid calculation end period within approved limit calculation end period yes excluding legally required employers contributions ahvivalv excluding bonuses roche remuneration report remuneration report roche security holdings related parties note remuneration corporate directors andr hoffmann andreas oeri financial statements roche holding ltd members founders families closely significant shareholders addition executive committee associated belong contractually bound december december shareholder group pooled voting rights respectively members board directors end group held shares persons closely associated held shares issued shares detailed information nonvoting equity securities nes shown resolution approval amount remuneration members group found finance report note table security holdings remuneration members corporate corporate executive committee roche group consolidated financial statements executive committee decided remuneration general provisions assigning authority decisions committees discretion taking account market corporate executive committee remuneration comparisons remuneration committee board security holdings shares nes directors outlined pages remuneration previous year board decision process approval framework december december directors separately submit total aggregate close relatives close relatives bonuses corporate executive committee members corporate executive security security general meeting financial year committee received remuneration work shares nes holdings others shares nes holdings others number number numbertype number number number numbertype number retrospectively binding approval shown amount remuneration board ceo severin schwan explained detail directors maximum amounts total aggregate ch franz remuneration corporate executive committee hoffmann period ordinary general meeting p baschera ordinary general meeting j bell tabled previous year general p bulcke meetings prospectively binding approval see julius rp lifton na na na na b poussot na na na na oeri schwan see security holdings see security holdings corporate executive committee corporate executive committee pr voser b weder di mauro total shares held shareholder group pooled voting rights listed roche remuneration report remuneration report roche highest total remuneration paid severin remuneration paid member corporate schwan member corporate executive executive committee see included committee total amount paid corporate executive severin schwan executive member board committee see total remuneration paid directors received remuneration primary members corporate executive committee function ceo reflected highest total highest total remuneration paid severin schwan member corporate executive committee chf base salary ssars rsus restricted stock units pension fundsmgbinsurances roche connect subtotal bonus subject approval total aggregate bonuses corporate executive committee annual general meeting blocked nonvoting equity securitiesshares psp payments expense allowancefor tax consulting services total calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value including employer contribution social securities beneficial parts detailed calculation remuneration see annual report number ssars grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee number rsus grant value chf nes closing price grant date march per rsu number rsus grant value chf nes average market price days period prior grant date march per rsu gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits shares blocked years calculation number shares based share price date transfer april approval agm target number bearer shares psp bearer shares multiplied per bearer share price averaged three months october december prior start performance cycle chf bearer share total estimated value annual report year psp award originally targeted nes awarded nes total spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security nes psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted nes nes respectively subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation originally targeted nes december december respectively according tsr achieved includes annual expense allowance chf payments tax consulting services chf chf additionally employer contribution ahvivalv chf chf paid form part compensation detidua base pay chf ayyoubi r diggelmann hippe g keller oday total including chf loss pension rights granted former employer contractual agreement detidua base pay members corporate executive committee bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting ayyoubi r diggelmann hippe g keller oday total detidua bonuses members corporate except severin schwan members executive committee corporate executive committee receive remuneration committee board directors bonus cash payment due determined corporate executive committee april severin schwan receive bonus members bonuses based performance form roche shares blocked years agreed objectives total aggregate bonus payment due april see amount bonuses brought forward binding vote annual general meeting roche remuneration report remuneration report roche stocksettled stock appreciation rights fair value ssars calculated grant ssars members corporate date using trinomial model american options executive committee trinomial model effective method ssars shown ssars table valuation american call options considers introduced roche january possibility exercising option time prior place stock options ssars entitle holders maturity called american option compared benefit financially increase value european option allows exercise roches nonvoting equity securities nes maturity date grant date exercise date strike price ssars terms multiyear plan numbers ssars strike prices expiry dates closing price roche nes grant date grant values ssars shown ssars vest three years grant date vested ssars table numbers ssars ssars exercised converted nes within calculated time issue entered seven years grant date unexercised ssars values table lapse without compensation stocksettled stock appreciation rights ssars chf ssars ssars ayyoubi r diggelmann hippe g keller oday total detidua restricted stock units rsus number value chf number value chf ayyoubi r diggelmann hippe g keller oday total calculation value consideration reduction value due additional blocking period years reduced market value calculation value consideration reduction value due additional blocking period years reduced market value calculation value number rsus multiplied grant value chf nes closing price grant date march per rsu calculation value number rsus multiplied grant value chf nes average market price days period prior grant date march per rsu information trinomial model american options please refer boyle phelim p lattice framework options pricing two state variables journal financial quantitative analysis volume issue mar wwwrochecomtrinomial modelpdf see strike prices table ssars detidua restricted stock units members remuneration component partially replacing ssars corporate executive committee value ssar awards reduced restricted stock units rsusrights receive non balance awarded form rsus voting equity securities threeyear vesting period plus value adjustment amount rsu awards allocated individually equivalent sum dividend paid remuneration committees discretion vesting period attributable number non vested recipient three years thereafter voting equity securities individual award resulting nonvoting equity securities may remain grantedwere introduced new blocked yearsroche remuneration report remuneration report roche performance share plan psp roche securities perform better average tsr roche securities nes shares ranked rsus corporate executive committee members corporate executive committee peer set roches tsr increases least th compared peer set companies operating replaced awarding additional psps members corporate executive committee cycle board directors elect industry therefore according therefore longterm incentive programmes members senior management currently increase nes award maximum award terms plan participants received corporate executive committee comprise individuals worldwide participate double originallevel reserved target number originally targeted nes see table psp ssar awards performance share plan psp nes according psp plan starting details psp cycle plus value adjustment future psp awards remuneration component psp consists overlapping threeyear performance amount equivalent sum dividend paid calculation psp values corresponding reserved corporate executive committee cycles new cycle beginning year vesting period attributable number reporting year newly based fair value enlarged corporate executive committee thus three cycles progress psp nonvoting equity securities individual grant bearer share prices averaged three psp psp whereas award granted requires roche months october december prior start longterm incentive programmes psp closed december securities perform well better performance cycle calculated per previous senior management comprise ssar targeted nes awarded psp per peer set event investment target amount roche securities entire rsu awards december targeted nes awarded roche securities underperforms average return psp threeyear cycle distribution one year historical psp performance see delivered peer companies fewer nes instead former calculation three awarded cycles corresponding distribution reporting provisions plan number non year ie cycles disclosed target remaining voting equity securities nes bearer shares bearer shares reserved plan cycle psp based actual value psp reserved participants cycle members corporate executive committee vesting year number securities actually awarded depend shown table whether extent investment roche board directors decide actual level securities shares nes outperforms average nes bearer shares cash equivalent awards performance share plan psp new calculation return investment securities issued peer psp cycles set peer companies comparisons based close financial years respectively fair value grant securities market prices dividend yields ie aim psp provide incentive per bearer share fair value grant total shareholder return tsr reduce effect participants achieve steady value growth bearer share per nes nes prices averaged prices averaged shortterm market fluctuations security prices three three averaged three months october december end psp cycle based months october months october december december prior start performance cycle threemonth average distributed dividends prior fair value prior fair value three months october december end totalling chf billion chf billion target number start target number target number start target number bearer shares performance cycle bearer shares nes psp performance cycle nes psp cycle chf billion chf billion psp psp number value chf value chf number value chf value chf schwan ayyoubi r diggelmann hippe ga keller oday total calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market see footnote value detiduaroche remuneration report remuneration report roche performance share plan psp former calculation total estimated total estimated awards value psp awards value psp target number targeted awards targeted awards roche bearer target number number nes number nes shares psp nes psp psp psp number number number value chf number value chf schwan ayyoubi r diggelmann hippe ga keller oday total total estimated value psp award originally targeted nes awarded excluding value adjustment added nes award spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security plus b psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted subject changes number value nes awardable plan december spread relevant period time ie year calculation value nonvoting equity securities consideration reduction value due blocking period years reduced market value plus c psp estimated value calculated using yearend price december chf per bearer share ro based number ro originally targeted subject changes number value ro awardable plan december spread relevant period time ie year calculation value shares consideration reduction value due blocking period years reduced market value board directors vote actual allocation originally targeted nes ro december december respectively according tsr achieved total estimated value annual report year psp award originally targeted nes awarded nes total spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted nes nes respectively subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation originally targeted nes december december respectively according tsr achieved detidua indirect benefits employer contributions chf pension payments pension payments funds annual taxtax funds annual taxtax mgb expense roche consulting mgb expense roche consulting insurances allowances connect services insurances allowances connect services ayyoubi r diggelmann hippe g keller oday total including employer contribution social securities beneficial parts indirect benefits members roche connect voluntary stock purchase plan corporate executive committee offering employees opportunity buy roche non employer contributions made social security voting equity securities nes amount equal schemes pension plans groupwide employee annual salary discount nes stock purchase plan roche connect respect purchased plan subject holding members corporate executive committee period four years switzerland shown indirect benefits employer contributions table employer contributions addition members corporate executive shown table committee received annual expense allowances members payments foreign tax obligations tax consulting services shown table detidua remuneration loans members remuneration former members corporate executive committee corporate executive committee based contractual obligations roche pensions totalling chf paidto individual members corporate executive chf paid former corporate committee childrens schooling costs executive committee members totalling chf chf total remuneration paid members aforementioned additional payments corporate executive committee included total remuneration members calendar year members corporate executive committee corporate executive committee received remuneration including bonuses totalling chf loans credits granted chf excluding additional employers members corporate executive committee contribution paid ahvivalv totalling chf chf maximum regular period notice members form part compensation corporate executive committee months changeofcontrol clauses employment contracts mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits detidua detidua detidua detidua roche paid legally required employers contributions members corporate executive committee total chf chf swiss beside legally required contributions separately social security programmes providing retirement stated ceo disability unemployment benefits ahvivalvroche remuneration report remuneration report roche additional remuneration bonuses severin schwan form roche shares prospective approvals members executive committees total future aggregate remuneration chf mentioned payments paid current former blocked years members members corporate executive committee corporate executive committee cash proposal agm agm agm payment see totalling chf respect aggregate amount aggregate amount aggregate amount executive remuneration subject approval financial year chf period period period annual general meeting excluding legally required employers contributions agm agm agm agm agm agm ahvivalv submit proposed total total aggregate amount proposal approval submission executive total aggregate amount ordinary annual general meeting approved agm bonuses binding vote annual general agm binding vote excluding legally required employers contributions ahvivalv excluding bonuses meeting board directors proposes awarding members corporate executive committee reconciliation reported remuneration excluding bonuses period ending shareholders prospectively approved ordinary agm remuneration members corporate retrospective approvals members executive committees total aggregate bonuses chf executive committee comparison ordinary agm ordinary ordinary agm approved remuneration agm remuneration amounted chf proposal agm agm agm corporate executive committee totalling excluding legally required employers contributions aggregate amount aggregate amount aggregate amount chf excluding legally required ahvivalv excluding bonuses psp assumption financial year financial year financial year employers contributions ahvivalv maximum value total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv prospectively approved total remuneration members executive committee comparison total remuneration chf submission executive total future amount executive total future aggregate total remuneration total remuneration total remuneration aggregate remuneration binding shareholder remuneration composed base pay longterm period period period vote incentives ssars calculated grant value without agm agm agm agm agm agm board directors proposes considering reductions value due blocking approval yet ordinary agm approve remuneration periods applicable psp calculated time maximum total remuneration approved agm required corporate executive committee totalling reservation nonvoting equity securities shares total remuneration calculation end period chf excluding legally required taking account maximal potential within approved limit yesno calculation end period yes employers contributions ahvivalv double contributions pension benefits excluding additional amount paid new members excluding bonuses period ending legally required employers contributions ahviv corporate executive committee approval ordinary agm alv well contributions expenses payments agm within approved total amount tax consulting services roche connect excluding legally required employers contributions ahvivalv excluding bonuses roche remuneration report remuneration report roche clawback according regulations psp programme shares nonvoting equity securities nes addition applicable statutory provisions roches originally targeted awarded nes shares december december longterm incentive plans include option partially shall lapse without compensation upon notice close relatives close relatives reclaim distributed compensation result special termination employment given reason shares nes security holdings shares nes security holdings circumstances clawback redundancy disability retirement number number numbertype number number numbertype corporate employee voluntarily serves notice termination guidelines security holdings executive employment ssars rsus unvested board directors decided ceo committee date termination employment lapse cec members must acquire shares andor schwan immediately without compensation nes equivalent two annual base salaries ceo ayyoubi one annual base salary respectively end r diggelmann upon termination employment result serious retain holdings long serve hippe misconduct ssars rsus granted cec exception roland diggelmann ga keller shares shares outstanding whether vested unvested shall lapse members corporate executive committee oday immediately without compensation according already fulfil requirement total shares shares ssars plan rules serious misconduct participant may include inter alia security holdings activity leading serious disciplinary action december december repeated willful failure perform duties respectively members cec persons reasonably assigned roche closely associated held securities violation law public regulation shown table shares nonvoting equity commission crime securities nes ssars restricted stock units gross negligence willful misconduct rsus employment engaging conduct bringing disgrace disrepute roche andor subsidiaries violation roches directives guidelines relating business conduct type security value acquired ceo shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary detiduaroche remuneration report remuneration report roche detidua detidua ssars restricted stock units rsus number ssars held december number rsus held december corporate executive corporate executive committee committee schwan schwan ayyoubi ayyoubi r diggelmann r diggelmann hippe hippe g keller g keller oday oday total total grant value per rsu chf chf chf price chf nes closing price grant nes average market price nes average market price date march days period prior grant date days period prior grant date market price per nes march march december chf expiry date grant value per ssar chf since trinomial model american call options v alues according corresponding annual reports options held former position options shown table issued roche employee stock options option entitles holder purchase one roche nonvoting equity security nes terms multiyear option plan strike price options shown closing price roche nes grant date options shown nontradable options subject vesting period one year vesting period two years vesting period three years unvested options lapse without compensation employment terminated voluntarily reasons retirement vested options must exercised within limited period timeroche report statutory auditor report statutory auditor roche report statutory auditor applied value components remuneration well assessing overall presentation remuneration report general meeting roche holding ltd believe audit evidence obtained basel sufficient appropriate provide basis opinion opinion audited accompanying remuneration auditors responsibility opinion remuneration report report dated january roche holding ltd responsibility express opinion year ended december roche holding ltd year ended december audit accompanying remuneration report conducted complies swiss law articles limited information according articles audit accordance swiss auditing ordinance ordinance excessive compensation standards standards require comply stock exchange listed companies ordinance ethical requirements plan perform contained sections marked blue line audit obtain reasonable assurance whether including respective footnotes pages remuneration report complies swiss law remuneration report articles ordinance kpmg ag responsibility board directors audit involves performing procedures obtain board directors responsible audit evidence disclosures made preparation overall fair presentation remuneration report regard compensation remuneration report accordance swiss law loans credits accordance articles ordinance excessive compensation ordinance procedures selected depend stock exchange listed companies board auditors judgement including assessment directors also responsible designing risks material misstatements remuneration ian starkey marc ziegler remuneration system defining individual report whether due fraud error audit also licensed audit expert licensed audit expert remuneration packages includes evaluating reasonableness methods auditor charge basel january roche independent assurance report independent assurance report roche procedures performed response assessed risks process determination impacted stakeholders peer consequently nature timing extent procedures competition review integration relevant regulatory gathering sufficient appropriate evidence deliberately requirements integration key organisational values limited relative reasonable assurance engagement objectives report prioritisation material aspects therefore less assurance obtained limited assurance inspecting integration sustainability risks independent assurance report engagement reasonable assurance engagement opportunities group risk management process adherence internal guidelines procedures selected depend assurance practitioners assessment processes data consolidation roche sustainability reporting judgement reviewing management ofand sustainability reporting processes contributions people key figures independence quality control assessing consolidation process data roche corporate governance sustainability committee environmental protection reporting guidelines published complied independence ethical group level roche holding ag basel roche european chemical industry council cefic requirements code ethics professional sustainability reporting guidelines g published accountants issued international ethics standards carried work data reported prior engaged perform assurance procedures global reporting initiative gri board accountants founded fundamental reporting periods performed work respect provide limited assurance aspects roche group internal corporate reporting manual principles integrity objectivity professional competence projections targets conducted work sustainability reporting roche included annual version group reporting manualsustainability due care confidentiality professional behaviour data outlined subject matter defined report report reporting firm applies international standard quality control roche materiality determination process based accordingly maintains comprehensive system quality believe evidence obtained sufficient scope subject matter sustainability reporting guidelines g published control including documented policies procedures appropriate provide basis assurance conclusions limited assurance engagement focused following global reporting initiative gri regarding compliance ethical requirements professional data information disclosed sustainability reporting defined guidelines people standards applicable legal regulatory requirements conclusion roche consolidated subsidiaries year ended contributions key figures sustainability risks based work performed described report december opportunities internally gathered collated summary work performed identified sustainability reporting nothing management reporting processes respect aggregated assurance procedures included amongst others come attention causing us believe sustainability reporting material aspects accuracy completeness sustainability indicators following work material respects preparation safety security health environmental subject inherent limitations given nature methods evaluation application roche group guidelines roche group internal sustainability reporting guidelines protection people key figures well related determining calculating estimating data reviewing application roche group internal based gri g sustainability reporting guidelines control environment relation data aggregation assurance report therefore read connection corporate sustainability contributions guidelines well cefic guidelines applied key figures roches internal guidelines definitions procedures site visits management inquiry internal reporting processes collect aggregate key figures including greenhouse gas emissions reporting sustainability performance visiting selected sites roches pharmaceuticals people data functioning designed provide scope scope resulting business travel diagnostics divisions usa canada uk appropriate basis disclosure compressed air liquid nitrogen tables graphs responsibility methodology china selection based quantitative internal reporting processes collect aggregate pages people key figures disclosed roche corporate governance sustainability qualitative criteria contributions data functioning designed pages report committee responsible subject matter interviewing personnel responsible internal sustainability provide appropriate basis disclosure consolidated data information roche group criteria well selection preparation presentation reporting data collection sites visited roche materiality determination process disclosed level relation contributions breakdown disclosed selected information accordance criteria roche group level determine understanding adhere principles guiding factors eg report responsibility form independent opinion based application roches internal sustainability guidelines soundness stakeholder determination peer review relevance materiality determination process roche group level limited assurance procedures whether anything assessment key figures regulatory environment integration key organisational according requirements gri g guidelines come attention indicate identified performing tests sample basis evidence supporting values objectives defined gri g disclosed pages report sustainability information selected contained report selected contributions people key figures ie design sustainability risks opportunities design sustainability risks opportunities stated material respects accordance roche accident rate energy consumption greenhouse gas determination process corporate level disclosed determination process based roche corporatelevel reporting criteria emissions related energy consumption halogenated function designed activities disclosed paragraph assessing hydrocarbons water waste contributions healthcare sustainability information mentioned subject sustainability risks opportunities report planned performed procedures accordance institutions patient organizations public policy bodies matter disclosed within sustainability reporting people key figures disclosed roches website within international standard assurance engagements isae philanthropic organizations headcountfte data roche annual report referenced section nonfinancial reporting subsection revised assurance engagements audits training hours concerning completeness accuracy section webpage stated accordance value employees reviews historical financial information standard adequacy consistency reporting criteria requires comply ethical requirements plan inspection documentation analysis relevant criteria perform assurance engagement obtain limited assurance policies principles zurich january management reporting processes respect identified sustainability information inspecting relevant documentation sample basis pricewaterhousecoopers ag sustainability reporting key figures assessed including roche group sustainability policies management internal policies procedures set forth limited assurance engagement isae revised reporting structures documentation following substantially less scope reasonable assurance inspecting principles roche materiality process roche group internal sustainability reporting guidelines engagement relation risk assessment procedures providing definition development adherence based responsible care health safety including understanding internal control gris environmental social economic reporting requirements addressing soundness identification christophe bourgoin bettina buomberger roche imprint imprint roche published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements group communications annual report contains certain forward basel switzerland looking statements forwardlooking statements tel may identified words believes expects wwwrochecom anticipates projects intends seeks estimates future similar expressions order publications discussion among things strategy goals tel plans intentions various factors may cause actual fax results differ materially future email baselwebmasterrochecom reflected forwardlooking statements contained annual report among others pricing media relations product initiatives competitors legislative tel regulatory developments economic conditions statement regarding earnings per share growth roche annual report published german email rochemediarelationsrochecom delay inability obtaining regulatory approvals profit forecast interpreted english bringing products market fluctuations mean roches earnings earnings per share investor relations currency exchange rates general financial subsequent period necessarily match report consists actual annual report tel market conditions uncertainties discovery exceed historical published earnings finance report contains email investorrelationsrochecom development marketing new products new earnings per share roche annual report annual financial statements uses existing products including without limitation consolidated financial statements per corporate sustainability committee negative results clinical trials research projects trademarks mentioned enjoy legal protection articles incorporation sense tel unexpected side effects pipeline marketed management reporting email corporatesustainabilityrochecom products increased government pricing pressures links thirdparty pages provided interruptions production loss inability convenience express opinion printed nonchlorine bleached fsccertified paper next annual general meeting obtain adequate protection intellectual property content thirdparty pages expressly march rights litigation loss key executives disclaim liability thirdparty information communications employees adverse publicity use news coverage believe urgent deliver medical solutions right noweven develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rochefhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche annual report aannnnuuaall rreeppoorrtt p e n p e p l e p r n e r improving diagnostics keeping pace emerging helping drive innovation new advancing medicine important market growth met goal collaborations strate pipeline news included clearance increasing representation gic partnership established molecular pointofcare people established foundation medicine provide strep test positive latestage developing regions experience new possibilities rd im study results multiple sclerosis key leadership roles proving patient care